Angiotensin ii- and vasopeptidase-inhibitory activities of gynura procumbens / Poh Ting Fung by Poh , Ting Fung
  
 
 
 
ANGIOTENSIN II- AND VASOPEPTIDASE- 
INHIBITORY ACTIVITIES OF 
GYNURA PROCUMBENS 
 
 
 
 
POH TING FUNG 
 
 
 
 
 
FACULTY OF MEDICINE 
UNIVERSITY OF MALAYA 
KUALA LUMPUR 
 
 
 
2014 
 
 
                                       
        P
O
H
 T
IN
G
 F
U
N
G
       
A
N
G
IO
T
E
N
S
IN
 II- A
N
D
 V
A
S
O
P
E
P
T
ID
A
S
E
- IN
H
IB
IT
O
R
Y
 
A
C
T
IV
IT
IE
S
 O
F
 G
Y
N
U
R
A
 P
R
O
C
U
M
B
E
N
S
 
M
M
ed
S
c 
2014 
  
 
 
ANGIOTENSIN II- AND VASOPEPTIDASE- 
INHIBITORY ACTIVITIES OF 
GYNURA PROCUMBENS 
 
 
 
 
 
 
POH TING FUNG 
 
 
 
 
 
DISSERTATION SUBMITTED IN FULFILMENT 
OF THE REQUIREMENT 
FOR THE DEGREE OF MASTER OF MEDICAL SCIENCE 
 
 
 
 
FACULTY OF MEDICINE 
UNIVERSITY OF MALAYA 
KUALA LUMPUR 
 
 
 
 
2014 
 
  
  
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ABSTRACT 
Blood pressure (BP) is partly determined by vasoconstriction or vasodilation.  The 
most important vasoconstrictor is angiotensin II (Ang II) whilst nitric oxide (NO), 
prostacyclin (PGI2) and bradykinin (BK) are main vasodilators.  The vasopeptidase, 
angiotensin-converting enzyme (ACE), is able to hydrolyse BK and convert angiotensin I 
(Ang I) to Ang II.  Bradykinin is also inactivated by another vasopeptidase, neutral 
endopeptidase (NEP).  Increases in ACE and NEP activities would elevate Ang II but 
decrease BK levels that could cause increases in BP which in the long-term could result in 
hypertension.   
Many antihypertensive drugs are available but with side-effects.  Alternative forms 
of treatments, especially those from the plant kingdom, are frequently sought after.  Gynura 
procumbens (G. procumbens) is widely used in folk medicine to treat hypertension.  
Previous findings show that leaves of this plant seem to decrease BP by inhibiting ACE 
activity and blocking calcium channels.  The aims of this project are to further study the 
BP-lowering properties of this plant by exploring the Ang II and ACE/NEP inhibitory 
activities of a partially purified fraction (FA-I) and to characterise the bioactive 
subfractions.   
Endothelium-intact and -denuded rat aortic rings suspended in organ chambers were 
used to study the effects of FA-I on Ang I- and Ang II-induced contractions.  The role of 
endothelium on the effects of FA-I was tested further by adding N
ω
-nitro-L-arginine methyl 
ester (L-NAME) or indomethacin to ascertain the involvement of NO and PGI2 respectively.  
Effects of FA-I on the vasodilatory response due to BK were studied by in vitro and in vivo 
methods.  Rats were also given oral doses of FA-I to examine the stability of the fraction 
against digestive enzyme degradation.  The FA-I fraction was subjected to further 
separation by thin layer chromatography (TLC) to obtain the FA-I subfractions, the 
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activities of which on ACE/NEP were analysed by spectrophotometric and 
spectrofluorometric assays.  After 
1
H-nuclear magnetic resonance analysis, one of the 
bioactive subfractions was sent for further structural characterisations.   
Results show that FA-I significantly (p<0.05) decreased the contraction evoked by 
Ang I and Ang II in endothelium-intact and -denuded rings with the degree of relaxation 
being significantly (p<0.05) higher in intact ones.  However, in the presence of L-NAME 
or indomethacin, the inhibitory effect of FA-I on Ang II-induced contraction was 
significantly (p<0.05) reduced.  In contrast, FA-I enhanced the vasorelaxant effects of BK, 
which may contribute to the greater BP-lowering effects of BK.  Activities of ACE and 
NEP was inhibited by FA-I.  Early-eluted subfractions obtained from TLC exhibited 
specific inhibition on ACE alone.  Study also shows that the ACE inhibitory activity of  
FA-I was still preserved after the actions of proteases and spectral analyses showed that 
FA-I subfractions may contain 16-carbon compounds.    
In conclusion, FA-I was found to be able to inhibit Ang II-induced contractions, 
probably via endothelium-dependent pathways by activating NO or PGI2 release, and also 
of being able to inhibit ACE/NEP activities.  Nuclear magnetic resonance and mass 
spectroscopic analyses indicate that one of the subfractions (FA-Ia) could be a 16-carbon 
compound but the precise structure remains to be elucidated. 
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ABSTRAK 
Tekanan darah (BP) ditentukan secara separa oleh aktiviti vasokonstriksi atau 
vasodilatasi.  Angiotensin II merupakan vasokonstriksi yang terpenting manakala nitrit 
oksida (NO), prostaglandin I2 (PGI2) dan bradikinin (BK) adalah vasodilatasi utama.  
Vasopeptidase, enzim pengubah angiotensin (ACE), mampu menyahaktif BK serta 
menukar angiotensin I (Ang I) kepada Ang II.  Bradikinin juga dinyahaktif oleh satu lagi 
vasopeptidase, neutral endopeptidase (NEP).  Peningkatan dalam aktiviti ACE dan NEP 
yang meningkatkan Ang II tetapi mengurangkan tahap BK boleh menyebabkan 
peningkatan BP yang dalam jangka masa panjang mengakibatkan hipertensi.  
Beberapa jenis ubat kini boleh didapati untuk mengawal hipertensi tetapi adalah 
dengan kesan sampingan.  Alternatif rawatan, terutamanya daripada alam tumbuhan sering 
dicari.  Gynura procumbens (G. procumbens) merupakan salah satu tumbuhan yang 
digunakan secara tradisi untuk merawat hipertensi.  Penemuan sebelum ini telah 
menunjukkan bahawa daun daripada tumbuhan ini mengenakan kesan antihipertensi 
seolah-olahnya melalui aktiviti perencatan ACE dan penyekatan saluran kalsium.  Jadi, 
projek ini bertujuan untuk terus mengkaji sifat penurunan tekanan darah tumbuhan ini 
dengan menerokai aktiviti perencatan Ang II dan ACE/NEP oleh fraksi akueus                    
G. procumbens yang separa tulen (FA-I) dan mencirikan subfraksi FA-I yang mempunyai 
bioaktiviti.  
Cincin aorta tikus dengan endotelium-tergantung dan -tidak tergantung yang 
dipasang dalam kamar organ telah digunakan untuk mengkaji kesan FA-I terhadap 
vasokonstriksi yang disebabkan oleh Ang I dan Ang II.  Peranan endotelium dalam kesan 
FA-I seterusnya diuji dengan menambah N
ω
-nitro-L-arginina methyl ester (L-NAME) atau 
indomethacin untuk memerhatikan penglibatan NO dan PGI2 masing-masing.  Kesan FA-I 
terhadap vasodilatasi yang dibawa oleh BK dikaji dengan kaedah in vitro dan in vivo.  
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Tikus juga disuap dengan FA-I untuk memeriksa kestabilan fraksi ini terhadap kemusnahan 
yang dibawa oleh enzim pencernaan.  Fraksi FA-I ditakluk kepada pemisahan lagi oleh 
lapisan nipis kromatografi (TLC) untuk mendapatkan subfraksi FA-I, di mana aktiviti-
aktiviti perencatan ACE/NEP dianalisis oleh spektrofotometer dan spektrofluorometer. 
Selepas analisis dengan 
1
H-resonans magnetik nuklear, salah satu subfraksi dihantar 
selanjutnya untuk pencirian struktur molekulnya.  
Keputusan menunjukkan bahawa FA-I dengan ketaranya (p<0.05) menurunkan 
vasokonstriksi oleh Ang I dan Ang II dalam cincin endotelium-tergantung dan -tidak 
tergantung di mana vasodilatasi lebih tinggi di endotelium-tergantung.  Walau 
bagaimanapun, dengan penambahan L-NAME atau indomethacin, kesan FA-I yang 
melarang vasokontraksi oleh Ang II telah berkurang dengan ketara (p<0.05).  Sementara itu, 
FA-I meningkatkan kesan vasodilatasi BK yang mungkin mengakibatkan penurunan BP 
yang lebih kuat.  Kesan penurunan tekanan darah oleh FA-I masih jelas walaupun selepas 
suapan menunjukkan bahawa aktiviti FA-I dapat menahani kesan enzim pencernaan.  
Tambahan pula, FA-I merencat aktiviti ACE dan NEP.  Dalam subfraksi-subfraksi yang 
didapati, hanya subfraksi yang didapati lebih awal oleh TLC memamerkan aktiviti 
perencatan yang spesifik pada ACE.  Baccan juga menunjukkan FA-I masih mengekalkan 
activiti perencatan ACE selepas tindakan oleh protease dan analisis spektra menunjukkan 
bahawa subfraksi FA-I mungkin mengandungi kompaun 16-karbon.  
Sebagai kesimpulannya, FA-I didapati berupaya mengurangkan vasokonstriksi yang 
dibawa oleh Ang II dengan endotelium mungkin memainkan peranan untuk mengaktifkan 
rembesan NO dan PGI2 di samping merencatkan aktiviti ACE/NEP.  Selain itu, analisis 
spektroskopi resonans magnetik nuklear dan spektrometri jisim menunjukkan bahawa salah 
satu daripada subfraksi (FA-Ia) mungkin adalah kompaun 16-karbon tetapi struktur yang 
tepat masih belum dijelaskan.  
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CHAPTER 1 - INTRODUCTION 
1.1  Blood pressure  
1.1.1  Regulation of blood pressure 
Blood pressure (BP) is the force exerted by the blood against any unit area of the 
blood vessel wall (Guyton and Hall, 2006).  The BP in humans is usually measured by the 
indirect auscultatory method and is expressed as systolic BP (SBP) over diastolic BP (DBP) 
(SBP/DBP) mmHg.  In physiology, BP can be calculated from the formula: BP = cardiac 
output (CO) x total peripheral resistance (TPR) (Kirkman and Sawdon, 2010).  Cardiac 
output is the volume of blood that is pumped out of the ventricle per minute and is 
expressed as CO = stroke volume (SV) x heart rate (HR) (Kirkman and Sawdon, 2010), 
whereas TPR refers to the total peripheral resistance of the entire systemic circulation.  In 
CO, SV is the volume of blood that is pumped out of the ventricles during one heart beat 
whereas HR is the number of beats per minute.  The SV is mainly controlled by venous 
return (preload), outflow resistance (afterload) and force of ventricular contractility 
(Ackermann, 2004; Wilcken, 2010).  Increases in preload and ventricular contractility, and 
a decrease in afterload will increase the SV.  As for the HR, it is mainly controlled by 
cardiac pacemaker cells that are increased by positive chronotropic agents (e.g. cardiac 
sympathetic nervous activity) and decreased by negative chronotropic agents (e.g. cardiac 
parasympathetic nervous activity) (Ackermann, 2004).   
Resistance in blood vessels largely depends on smooth muscle activities that change 
the radius of the lumen, either by vasocontraction or vasodilation.  Vascular smooth muscle 
(VSM) activities are affected by the endothelium, autonomic nervous system and blood 
bornes substances such as adrenaline, acetylcholine, adenosine triphosphate (ATP) and 
substance P (Kirkman and Sawdon, 2010).  Overall, any factor that influences SV, HR and 
TPR will change the BP (Kirkman and Sawdon, 2010).  
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In order to provide and maintain sufficient blood supply to organs and tissues, BP is 
regulated all the times, either by short-term or long-term mechanisms.  Under resting 
conditions, arterial BP is controlled mainly by baroreceptors (Kirkman and Sawdon, 2010) 
via altering the cardiovascular parameters of SV, HR or TPR (Ackermann, 2004).  In this 
short-term regulation of BP, the change in the stretch of arterial walls is rapidly sensed by 
baroreceptors located in the walls of aortic arch and carotid sinuses (Kirkman and Sawdon, 
2010) that reflexedly activate or inhibit the sympathetic or parasympathetic division of the 
ANS and renin-angiotensin system (RAS).  In the long-term regulation of BP, however, the 
kidney plays the most important role (Ackermann, 2004) by regulating the total body 
content of sodium, water and other electrolyte balance.   
In addition, circadian rhythm also plays a key role in BP regulation.  In a healthy 
person, the BP rises in the morning, followed by night time drop in a cycle that occurs once 
every 24 hours (Rudic and Fulton, 2009).  This circadian rhythm may become abnormal 
during hypertension in which the person may become nondippers (absence of nocturnal BP 
drop), extreme dippers (marked nocturnal BP drop) or reverse dippers (rise in nocturnal BP) 
(Rudic and Fulton, 2009).  
 
1.1.2 Endothelium 
The endothelium is a monolayer of cells lining the entire inner layer of blood 
vessels.  This layer represents an important component in inflammation, platelet 
aggregation, angiogenesis, endocrine functions (Feletou, 2011) and the regulation of 
vascular contractility by releasing vasoactive substances that change the degree of 
contraction of the underlying VSM (Vanhoutte and Mombouli, 1996).  The vasoactive 
substances produced by the endothelium are vasodilators such as nitric oxide (NO) and 
prostacyclin (PGI2) that cause endothelium-dependent hyperpolarisation (EDH) (Feletou 
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and Vanhoutte, 2013) or vasoconstrictors such as endothelin-1 (ET-1) and thromboxane A2 
(TXA2) that presumably result in membrane depolarisation (Sandoo et al, 2010).  Another 
powerful vasoconstrictor is that of angiotensin II (Ang II) and it is discussed in the RAS 
section (page 11).     
 
1.1.2.1 Nitric oxide 
Nitric oxide, first identified by Furchgott and Zawadzki in 1980 (Furchgott and 
Zawadzki, 1980) is an important component in the control of basal vasodilator tone in 
blood vessels (Vallance et al, 1989).  This compound is formed from L-arginine by the 
action of NO synthase (NOS), an enzyme that exists in three isoforms: neuronal NOS, 
macrophage or inducible NOS and endothelial NOS (eNOS) (Vanhoutte and Mombouli, 
1996).  Of these, eNOS appears to play a main role in dilation of blood vessels (Sandoo et 
al, 2010).  Figure 1.1 summarises the formation of NO by activation of eNOS.  Stimuli 
such as shear stress and the binding of NO agonists such as bradykinin (BK), acetylcholine 
(ACh), insulin or substance P to respective receptors increase intracellular calcium ion 
(Ca
2+
)
 
([Ca
2+
]i) and cause calmodulin in the endothelial cells to bind to eNOS that then 
converts L-arginine to NO.  The released NO then diffuses into smooth muscle cells and 
activates soluble guanylate cyclise (GC), which converts guanosine triphosphate (GTP) to 
cyclic guanosin-3‘, 5-monophosphate (cGMP) (Sandoo et al, 2010).  Subsequently, a 
protein kinase is activated by cGMP to inhibit calcium influx into the smooth muscle cells 
which then decreases the contraction of smooth muscle cells to cause vasodilation (Galley 
and Webster, 2004).   
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1.1.2.2 Prostacyclin and thromboxane A2 
Although both PGI2 and TXA2 are prostanoids, they have opposing effects on VSM 
in that PGI2 is a vasodilator whereas TXA2 is a vasoconstrictor.  The enzyme that is 
involved in the formation of PGI2 and TXA2 is cyclooxygenase (COX), wherein two 
isoforms of COX: COX-1 which is expressed in endothelial cells and other tissues; and 
COX-2 which is expressed during endothelial damage or in the presence of various 
cytokines (Feletou, 2011).  Both isoforms are involved in the synthesis of PGI2 and TXA2 
and the synthesis of either depends on the types of tissues and on whether there is 
inflammation or other influences (Feletou, 2011).   
In the normal healthy condition or in the presence of stimuli such as oxidative stress, 
PGI2 is constitutively produced in the endothelial cells from prostaglandin H2 by the actions 
of prostacyclin synthase (Tang and Vanhoutte, 2008).  The PGI2 then binds to its receptor 
(IP receptor) to activate adenylate cyclase that induces the production of cyclic adenosine-
Figure 1.1 : Schematic representation of the activation of endothelial nitric oxide synthase 
that finally produces nitric oxide to cause vasodilation (reproduced with permission). 
(adapted from Galley and Webster, 2004)  
NOTES: NOS = nitric oxide synthase; GC = guanylate cyclise; GTP = Guanosine 
triphosphate; cGMP = cyclic guanosin-3’, 5-monophosphate 
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3‘, 5-monophosphate (cAMP) (Vanhoutte and Mombouli, 1996) to cause vasodilation 
(Fetalvero et al, 2007).   
Thromboxane A2 is also produced from prostaglandin H2, by the actions of 
thromboxane A synthase (Yokoyama et al, 1991).  In healthy VSM or presence of physical 
stimuli such as stretch, this unstable compound with a short half-life (about 30 seconds) 
binds to its receptor (TP receptor) to cause platelet aggregation, angiogenesis, and 
endothelium-dependent contractions by increasing [Ca
2+
]i (Nakahata, 2008).  
 
1.1.2.3 Endothelin-1  
Endothelin (ET) is a strong vasoconstrictor and exists in three isoforms: ET-1, ET-2 
and ET-3 (Inoue et al, 1989).  Endothelin-1, the only isoform produced in vascular 
endothelium (Masaki, 2004), is formed from big ET-1 by the action of endothelin-
converting enzyme, a zinc-metallopeptidase that is anchored to the plasma membrane 
(Yanagisawa et al, 1988).   
In tissues, two types of ET-1 receptors are found: ETA and ETB (Luscher, 1994).   
Endothelin-1 binds to these receptors, predominantly ETA (Luscher, 1994) to increase 
[Ca
2+
]i and cause vasocontraction (Zhang
1
, 2000).  However, under certain conditions,   
ET-1 can cause vasodilation via the activation of ETB receptor, by stimulating the release of 
NO (Cardillo et al, 2000). 
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1.2 Renin-angiotensin system 
1.2.1 Overview  
The main homeostatic mechanism in the body that is involved in the regulation of 
BP, as well as extracellular fluid volume and sodium content balance is RAS (Lote, 2006).  
In the RAS, the key enzyme renin, is synthesised in an inactive form as ‗prorenin‘ in the 
granular cells of the afferent arterioles in the juxtaglomerular (JG) cells of the kidneys 
(Guyton and Hall, 2006).  Renin splits 10-amino acid fragments from angiotensinogen that 
is produced in the liver to form the decapeptide angiotensin I (Ang I) which has no 
physiological effect (Hayashi and Kimoto, 2010) and within seconds to minutes, it is 
cleaved of two amino acids to form octapeptide Ang II by an enzyme called angiotensin-
converting enzyme (ACE) (Guyton and Hall, 2006; Lote, 2006).  Although the Ang II 
persists in the blood for 1-2 minutes only, it accounts for the main function of RAS to 
restore the BP to the normal level (Guyton and Hall, 2006).   
The RAS is involved in both physiological and pathological processes.  In the 
physiological processes, RAS takes part in development, learning and memory as well as 
tissue growth.  However, in pathological process, RAS plays a role in the progression of 
disorders such as diabetes, hypertension, cardiovascular disease (CVD) and also tumors 
(Nguyen, 2006; Atlas, 2007).  The roles and characteristics of renin, Ang II, ACE and the 
roles of receptors for angiotensin II are shown in Figure 1.2.  
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Inactive metabolites 
Stimulation of renin release 
    SNS 
   Wall tension in renal afferent arteriole 
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+
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Figure 1.2 : Activation of renin-angiotensin system and the effects on related receptors as 
well as the actions of neutral endopeptidase (adapted from Ferrario and Iyer, 1998; Turner 
and Hooper, 2002; Carey and Park, 2006; Hunyady and Catt, 2006; Atlas, 2007; Daull et 
al, 2007; Lambert et al, 2008; Harrison-Bernard, 2009; Benigni et al, 2010). 
 
 
NOTES: SNS = Sympathetic nervous system; Ang = Angiotensin; ACE = Angiotensin converting enzyme; 
BK = Bradykinin; NPs = Natriuretic peptides; NEP = Neutral endopeptidase; AT1R, AT2R = Angiotensin 
type 1, 2 receptor;  
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Angiotensinogen 
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NEP 
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8 
 
1.2.2 Renin  
Renin is the key regulatory enzyme in the RAS (Sequeira Lopez and Gomez, 2010) 
and it exists in plasma in two forms: inactive prorenin (about 90%) and mature renin 
(Nguyen, 2006).  The inactive prorenin becomes mature renin in the JG cells of the kidneys, 
which is then released into the plasma when triggered by the three main mechanisms that 
are increased sympathetic activity to the granular cells of the afferent arterioles, decreased 
tension in the walls of the afferent arterioles and decreased delivery of sodium chloride to 
the macula densa (Lote, 2006).  In addition, renin expressing cells are restricted to JG cells 
only (Sequeira Lopex et al, 2004).  However, in conditions such as hemorrhage that 
triggers the homeostasis response, there is an increase in renin expressing cells outside the 
JG cells such as in renal vascular smooth muscle cells and glomerular cells (Sequeira 
Lopex et al, 2004).  This is useful in order to produce enough renin to reestablish 
homeostasis (Sequeira Lopex et al, 2004).   
 
1.2.3 Angiotensin-converting enzyme 
Angiotensin-converting enzyme, a zinc ion (Zn
2+
)-dependent dipeptidyl 
carboxypeptidase and an ectoenzyme, is anchored to cell membranes by C-terminal (Shen 
et al, 2008).  It exists as two isoforms: somatic ACE (sACE) (Bernstein et al, 1988) which 
is found in many tissues such as vascular endothelia (Ryan et al, 1976), endothelial lining 
of lungs (Turner and Hooper, 2002), brush borders of kidney and intestine (Cushman and 
Cheung, 1971); and the testicular or germinal ACE (gACE) isoform which is located only 
in testes (Bernstein et al, 1989).  Somatic ACE has two active sites with two domains (C- 
and N-domains) whereas gACE has only one active site (C-domain), which is identical to 
the C-domain of sACE (Ehlers et al, 1989).   
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In general, ACE functions by hydrolysing Ang I, BK, substance P and 
cholecystokinin (Turner and Hooper, 2002) as well as cleaving Ang (1-7) (Chappell et al, 
1998).  Both the domains of sACE are believed to have distinct functions wherein the       
C-domain is involved in RAS regulation and BK hydrolysis, whereas the N-domain is 
connected with the processing of bioactive peptides and regulation of renal structure and 
functions (Coates, 2003).  In contrast, the C-domain in gACE is involved in the sperm 
maturation process (Metayer et al, 2002; Coates, 2003).  Nevertheless, these two isoforms 
of ACE cannot act as a substitute for each other in their respective physiological functions 
(Kessler et al, 2007).     
 
1.2.4 Angiotensin-converting enzyme 2  
A homologue for ACE that shares 42% of amino acid sequence with ACE is ACE 2.  
It is less distributed and restricted to the heart, kidney and testes (Donoghue et al, 2000).  
There are differences in the structures and actions of ACE homologues in which ACE is a 
dipeptidyl carboxypeptidase that cleaves dipeptides from substrate whereas ACE 2 is a 
carboxypeptidase that cleaves only one single amino acid from its substrate (Guy et al, 
2005; Lambert et al, 2008).   
In the RAS, ACE 2 cleaves Ang I to form angiotensin (1-9) [Ang (1-9)] and also 
splits Ang II to angiotensin (1-7) [Ang (1-7)], a compound which is becoming popular for 
their protective role in RAS.  The Ang (1-9) is also converted by another ectoenzyme, the 
neutral endopeptidase 24.11 (NEP), and also by ACE to form Ang (1-7) (Welches et al, 
1993).  Studies have shown that Ang (1-7) potentiates the effect of BK (Greco et al, 2006), 
stimulates NO and prostaglandin release (Rajendran, Chirkov et al. 2005) but antagonises 
the effect of Ang II (Grobe et al, 2007).  The affinity of ACE 2 for Ang I is weaker when 
compared to ACE and the imbalance in the level of ACE and ACE 2 in the body is believed 
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to be responsible for CVD and also hypertension (Der Sarkissian et al, 2006).  Other than 
that, a report shows that ACE 2 is a receptor for severe acute respiratory syndrome (SARS) 
coronavirus (Li et al, 2003).   
 
1.2.5 Neutral endopeptidase 
Another Zn
2+
-dependent metalloendopeptidase that is also involved in BK 
metabolisms (Figure 1.2), is neutral endopeptidase (NEP), also known as enkephalinase, 
neprilysin, neutral metalloendopeptidase or common acute lymphoblastic leukemia antigen.  
Similar to ACE, NEP also exists in the membrane-bound form and it is widely distributed 
in kidneys, the central nervous system, lungs, male genital tract, intestines, and in 
neutrophils, fibroblasts and epithelial cells (Erdos and Skidgel, 1989).  
Neutral endopeptidase metabolises vasoconstrictor peptides such as enkephalins and 
Ang II as well as the vasodilator peptides, BK, substance P and natriuretic peptide (NP) 
(Ruschitzka et al, 2001).  The main effect of NEP is similar to ACE that is to increase BP.  
Although ACE is the main enzyme in the metabolism of BK, in human cardiac tissues, 
NEP is more important in metabolising BK (Kokkonen et al, 1999).  The most important 
role of NEP is in the metabolism of NPs which present in three isoforms: the well-studied 
atrial-NP (ANP), brain-NP and C type-NP (Ruschitzka et al, 2001).  The ANP reduces BP 
by increasing natriuresis as well as inhibiting RAS, endothelin and angiogenesis 
(Ruschitzka et al, 2001; Sagnella, 2002).   
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1.2.6 Angiotensin II 
Angiotensin II binds to two types of G protein-coupled receptors, known as Ang II 
type 1 receptor (AT1R) and type 2 receptor (AT2R) (Lote, 2006; Benigni et al, 2010).  
Angiotensin II type 1 receptor is widely distributed especially in VSM cells (Hunyady and 
Catt, 2006) and it mediates most of the actions of Ang II (Lote, 2006) which vary at 
different effector tissues (Peach and Dostal, 1990).  For instance, Ang II is a 
vasoconstrictor in systemic circulation (Peach and Dostal, 1990) but has both vasodilator 
and vasoconstrictor effects in cerebral circulation (Maktabi et al, 1990).  Nevertheless, the 
overall main effect of Ang II is to increase BP by causing vasocontraction and this 
contraction is a fast reaction and occurs rapidly after Ang II binding to AT1R (Touyz and 
Schiffrin, 2000).  Increased production of Ang II due to increased RAS activity is 
considered one of the many contributing factors for the onset of hypertension (Navar et al, 
2011).  Table 1.1 summarises the effects brought about by activation of AT1R by Ang II. 
In contrast, the level of AT2R is low in healthy adults but only exists at high level in 
fetal tissues (Ichiki et al, 1995) and pathological states such as heart failure (Liu et al, 1997) 
and myocardial infarction (Searles and Harrison, 1999).  This receptor may take part in 
brain development as well (Gendron et al, 2003).  Stimulation of AT2R by Ang II 
antagonises the effects brought by AT1R activation (Benigni et al, 2010) and also activates 
the BK type 2 (B2) receptor to cause vasodilation which is likely to be mediated by the NO 
pathway and cGMP cell signalling cascade (Searles and Harrison, 1999; Carey and Park, 
2006). 
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 Vasoconstriction  
 Stimulation of thirst 
 Release of antidiuretic hormone and aldosterone  
 Increased sodium reabsorption by direct effects on the proximal tubule of the 
nephrone, effect of aldosterone on distal tubules and also increase in renal 
sympathetic nerve activity 
 Angiogenesis, cellular growth and hypertrophy 
 Induction of production of reactive oxygen species (ROS)  
 Increase in the production of vascular endothelial growth factor in the inflammatory 
process  
(Adapted from Searles and Harrison, 1999; Hunyady and Catt, 2006; Lote, 2006; Benigni 
et al, 2010) 
 
Angiotensin II has a short half-life of about one minute (Lote, 2006).  It is cleaved 
by aminopeptidase A to angiotensin III (Ang III) which has the same affinity for AT1R and 
AT2R.  Angiotensin III plays a main role in the regulation of brain RAS as well as 
stimulating the release of aldosterone.  It is then cleaved by aminopeptidase N to 
angiotensin IV (Ang IV) which has low affinity for AT1R and AT2R (Hunyady and Catt, 
2006) but a higher affinity for angiotensin type 4 receptor (AT4R) to increase natriuresis 
and renal blood flow.  Angiotensin IV is also involved in memory and learning process 
(Turner and Hooper, 2002).  
     
 
 
 
 
 
Table 1.1 : Effects of angiotensin II type 1 receptor activation. 
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1.2.7 Non angiotensin-converting enzyme dependent angiotensin II formation 
Angiotensin II can also be formed from non-ACE dependent pathway and the 
enzyme responsible for this is chymase (Huang et al, 2003).  Chymase, a chymotrypsin-like 
serine protease found in the mast cells (Takai et al, 1999), is thought to be the main enzyme 
for Ang II formation in human hearts (Urata et al, 1990), arteries (Huang et al, 2003) and 
the kidneys (Huang et al, 2003).  This pathway provides a need to suppress the non ACE-
dependent Ang II formation in order to fully suppress the RAS (Petrie et al, 2001). 
 
1.3 Kallikrein-kinin system 
1.3.1 Overview  
The kallikrein-kinin system is a complex system that has a close relationship with 
the RAS in the regulation of BP.  There are three main constituents in the kallikrein-kinin 
system: kallikreins, kininogens and kinins (Campbell, 2000).  Kallikreins are serine 
proteases and can be classified into tissue kallikrein and plasma kallikrein.  Kininogens are 
proteins of two types: low molecular weight kininogen (LMWK) and high molecular 
weight kininogen (HMWK).  The kallikrein-kinin system produces two main kinins which 
are BK and kallidin.   
The kallikrein-kinin system is predominantly found in tissues rather than in the 
circulation (Golias et al, 2007).  As shown in Figure 1.3, the precursor for plasma kallikrein 
is prekallikrein that forms a complex with Factor XII (Hageman Factor).  When there is 
tissue damage, prekallikrein is changed to plasma kallikrein that then converts HMWK to 
BK while tissue kallikrein hydrolysess LMWK to kallidin that will eventually be converted 
to BK by aminopeptidase (Campbell, 2000).  
There are two types of G-coupled protein receptors for BK, known as BK type 1 (B1) 
and B2 receptors.  The B2 receptor predominates under healthy conditions whereas the B1 
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receptor is induced by tissues injuries such as myocardial ischemia and inflammation and 
also by endogenous factors such as growth factors, endotoxins and cytokines (Campbell, 
2000; Sharma and Al-Sherif, 2011).  When the B1 receptor is activated, it causes 
vasodilation and initiates the inflammatory response (Sharma and Al-Sherif, 2011).  As for 
B2 receptor, it has higher affinity for BK (Leeb-Lundberg et al, 2005) and activation of B2 
receptor causes vasodilation by releasing EDH mediators and cGMP from NO (Vanhoutte, 
2001).  Figure 1.3 shows the activation of kallikrein-kinin system that leads to the 
production of kallidin and BK as well as the actions of BK receptors.  
Kinin receptors are also linked to many types of diseases such as CVD, renal 
disease, airway disease especially asthma (Barnes 1992), neurological disease, cancer as 
well as arthritis, hereditary angioedema and gastrointestinal disease (Leeb-Lundberg et al, 
2005).  Thus, kinin receptors are also a pharmacological target in treating these diseases.  
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NOTES: 
LMWK = Low molecular weight kininogen; 
HMWK = High molecular weight kininogen;  
B1R, B2R = Bradykinin type 1, type 2 receptor  
 
Aminopeptidase 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Bradykinin 
Bradykinin is important in the regulation of BP and pain and in the inflammatory 
process, and it is also said to have cardioprotective (Sharma and Al-Sherif, 2011), diuretic 
and natriuretic effect (Willis et al, 1969).  Binding of BK to B2 receptor increases local 
production of BK to induce endothelium dependent relaxation and the main action of BK is 
at the heart, kidney and blood vessels (Vanhoutte, 2001).  In the inflammatory process, BK 
increases vascular permeability to fluid and plasma proteins that results in oedema (Sharma 
and Al-Sherif, 2011) while in the management of pain, BK is both algesic and hyperalgesic 
(Sharma and Al-Sherif, 2011).   
Degradation of BK occurs either at its amino or carboxy terminal (Figure 1.4).  
Enzymes that cleave at amino terminal are aminopeptidase M and P whereas enzymes that 
are responsible for the degradation of BK at carboxy terminal are kininase I and kininase II 
Kininogens 
LMWK HMWK 
Kallidin Bradykinin 
B2 receptor 
(predominates) 
-vasodilation 
-inflammation 
-diuresis and natriuresis 
B1 receptor 
-vasodilation 
-inflammation 
Prekallikrein + 
Hageman factor 
Plasma  
kallikrein 
Tissue 
kallikrein 
Figure 1.3 : Activation of kallikrein-kinin system that finally leads to activation of 
bradykinin receptors (B1 and B2) (adapted from Campbell, 2000 and Sharma and Al-
Sherif, 2011). 
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BRADYKININ 
(Sharma and Al-Sherif, 2011).  Kininase I includes carboxypeptidase M and N whereas 
kininase II are ACE and NEP (Dorer et al, 1974; Kokkonen et al, 1999; Sharma and Al-
Sherif, 2011).  Figure 1.4 shows the enzymes that degrades BK at its amino or carboxy 
terminal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A C 
Kininase I 
Carboxypeptidase M 
Carboxypeptidase N 
 
 
Kininase II 
ACE 
NEP 
 
Figure 1.4 : Degradation of bradykinin that occurs at amino (A) and carboxy (C) 
terminals. 
 
NOTES: 
ACE = Angiotensin converting enzyme;  
NEP = Neutral endopeptidase 
Aminopeptidase M 
Aminopeptidase P 
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1.4  Hypertension 
1.4.1  Overview  
Hypertension or high BP occurs when the body fails to bring the BP back to the 
normal set-point.  Hypertension is generally regarded as chronic elevation of BP ≥140/90 
mmHg.  It is called ‗silent killer‘ because it is asymptomatic and can cause severe health 
problems and even death (Rudic and Fulton, 2009).  Hypertension is classified into primary 
or secondary hypertension.  Primary, also well-known as essential or idiopathic 
hypertension accounts for 95% of all cases of hypertension and it is referred to the 
hypertensive condition in which secondary causes such as renal failure, pheochromocytoma 
and aldosteronism are absent (Carretero and Oparil, 2000).  Secondary hypertension is the 
hypertension in which the underlying causes such as kidney diseases, sleep apnea, 
hormonal diseases and vascular diseases are known.  According to The Seventh Report of 
the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) (Chobanian et al, 2003), for adults 18 years old and older, their BP 
can be classified into normal, prehypertension and hypertension (stage 1 and stage 2) 
(Chobanian et al, 2003), as shown in Table 1.2. 
However, the definition for hypertension by JNC 7 which is according to the BP 
threshold method lacks the ability to identify underlying CVDs in people with normal BP 
(Giles et al, 2005).  Thus, a writing group within the American Society of Hypertension has 
produced a new definition of hypertension which takes into account different physiological 
abnormalities in the cardiovascular system as well as other organs caused by hypertension.  
They define hypertension as ―a progressive cardiovascular syndrome arising from complex 
and interrelated etiologies.  Early markers of the syndrome are often present before blood 
pressure elevation is observed; therefore, hypertension cannot be classified solely by 
discrete blood pressure thresholds.  Progression is strongly associated with functional and 
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structural cardiac and vascular abnormalities that damage the heart, kidneys, brain, 
vasculature, and other organs, and lead to premature morbidity and death.‖ (Giles et al, 
2005; Giles et al, 2009) 
 
 
Notes: BP = Blood pressure; SBP = Systolic BP; DBP = Diastolic BP 
 
1.4.2 Global burden of hypertension 
In 2000, more than 25% of the adult population in the world was estimated to have 
hypertension and it is predicted that 1.56 billion adult population will have hypertension by 
2025 (Kearney et al, 2005; Kim et al, 2010).  The overall prevalence of hypertension for 
subjects aged ≥18 years in the United States in 2003-2004 was 29.3% (Ong et al, 2007).  In 
Malaysia, the prevalence of hypertension for subjects aged ≥15 years was 40.5% in 2004 
(Rampal et al, 2008).  
Hypertension is the most common risk factor for CVD and end organ damage 
which are the main cause for mortality and morbidity worldwide (Foex and Sear, 2004; 
Schmieder, 2010).  According to JNC 7, individuals with BP between 130-139/85-89 
mmHg have more than twice the risk of getting CVD than individuals with BP below 
120/80 mmHg (Chobanian et al, 2003).  Although the morbidity and mortality that linked 
BP Classification SBP (mmHg) DBP (mmHg) 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Stage 1 hypertension 140-159 or 90-99 
Stage 2 hypertension ≥160 or ≥100 
Table 1.2 : Classification of blood pressure for adults ≥18 years old according to The 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (Chobanian et al, 2003).  
 
19 
 
to hypertension is high, the control of BP to optimal level among hypertensive patients is 
less than 50% (Foex and Sear, 2004; Jackson et al, 2008; Nahas, 2008).   
 
1.4.3 Risk factors for hypertension 
Blood pressure is the product of CO and TPR which means that hypertensive 
patients may have increased CO, increased TPR or increased in both of these parameters 
(Foex and Sear, 2004).  Increase in any of these parameters rise the BP.  Table 1.3 shows 
some of the identifiable risk factors for hypertension. 
 
Unchangable factors: 
- Genetics (Lifton, 1995; Agarwal et al, 2005) 
- Aging (Chobanian et al, 2003; Lee and Oh, 2010) 
- Gender (Dubey et al, 2002) 
Behavioral factors: 
- High alcohol and salt intake (Carretero and Oparil, 2000) 
-     Stress (Dogru et al, 2010; Joyner et al, 2010) 
- Sleep deprivation (Gangwisch et al, 2006) 
Other factors: 
- Obesity (Strazzullo et al, 2001; Beltowski, 2010) 
- Diabetes (Esler et al, 2006; Kotsis et al, 2010) 
 
  
Table 1.3 : Identifiable risk factors for hypertension. 
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1.4.4 Treatments for hypertension 
In general, the treatment goal in the control of BP for hypertensive patients is 
<140/90mmHg while the goal for hypertensive patients with diabetes or renal diseases is 
<130/80mmHg (Chobanian et al, 2003).  The algorithm for the treatment of hypertension 
by JNC 7 is shown in Figure 1.5.  According to JNC 7, the first line of treatment for 
hypertension is lifestyle modification which includes weight reduction, adoption of the 
Dietary Approaches to Stop Hypertension (DASH) eating plan, dietary sodium reduction, 
regular physical activity and moderation of alcohol consumption (Chobanian et al, 2003).  
The DASH eating plan includes diet high in vegetables, fruits, low-fat dairy products with 
smaller amount of red meat and sugar intake, and with decreased amount of total and 
saturated fat and cholesterol (Sacks et al, 2001).  Combination of this eating plan and 
dietary sodium reduction has been proven to be effective in reducing BP (Sacks et al, 2001). 
If lifestyle modification fails to control the BP at normal levels, pharmacological 
treatment will be considered by physicians.  Choices of drugs rely on their BP lowering 
effects and also consideration of potential CVD risk (Gradman et al, 2010).  Generally, 
there are five main classes of drugs that are popularly used in treating hypertension, and 
they  are low-dose thiazide diuretic, beta blocker (BB), calcium channel blocker (CCB), 
ACE inhibitor (ACEI) and angiotensin receptor blocker (Hill and Smith, 2005).  Among 
them, low dose thiazide-diuretics are the first line of drug treatment for most hypertensive 
patient without complications (Hill and Smith, 2005).   
In selecting the classes of drugs for treatment, circadian rhythms have to be taken 
into consideration whenever possible due to the efficacies of many antihypertensive drugs 
vary at different times of administration (Lemmer, 2006).  For instance, it is advisable that 
antihypertensive drugs given to dippers (nightly drop in BP) should be in the early morning, 
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whereas in non-dippers it should be at evening; or add an extra evening dose in addition to 
morning dose (Lemmer, 2006).  
Hypertension becomes more difficult to be treated if resistant hypertension develops.  
Resistant hypertension means that BP of the patient is consistently above the goal level 
despite being treated with a combination therapy of at least three different classes of 
antihypertensive agents (Viera and Hinderliter, 2009).  Non-compliance of patient is 
considered the main reason for resistant hypertension (Thrall et al, 2004) and this can be 
due to misunderstanding of patient about the medication regimen, adverse side-effects of 
drugs or poor patient-doctor relationship (Thrall et al, 2004).  An interesting study 
conducted by (Ross et al, 2004) shows that hypertensive patients who believed that the 
treatment is necessary for them or who are more confident that the treatment actually works 
are likely to be more compliant to the said treatment.  In addition to the five major classes 
of drugs, other types of drugs are direct vasodilators, alpha-1 adrenoceptor blocker and 
central alpha-2 agonist.  Table 1.4 shows the examples for the classes antihypertensive 
drugs and their possible side-effects.  
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NOTES: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta 
blocker; CCB, calcium channel blocker; AldoAnt, aldosterone antagonist 
 
 
 
 
 
Lifestyle modifications 
Not at target BP (<140/90 mmHg for all hypertensive and <130/80 mmHg for 
hypertensive patients with diabetes or renal disease) 
With compelling indications 
 
Heart failure 
Diuretic, BB, ACEI, ARB or AldoAnt 
Postmyocardial infarction 
BB, ACEI or AldoAnt 
High coronary disease risk 
Diuretic, BB, ACEI or CCB  
Diabetes 
Diuretic, BB, ACEI, ARB or CCB 
Chronic kidney disease 
AECI or ARB 
Recurrent stroke prevention 
Diuretic or ACEI 
 
 
Without compelling indications 
 
Stage 1 hypertension 
Thiazide-type diuretics for most 
May consider ACEI, ARB, BB, CCB, 
or combination 
 
Stage 2 hypertension 
Two-drug combination for most  
(usually thiazide-type diuretic and  
ACEI, or ARB, or BB, or CCB) 
 
 
 
 
 
Initial drug choices 
Not at target BP 
Optimise dosages or add additional drugs until goal BP is achieved. 
 
Figure 1.5 : The algorithm for the treatment of hypertension according to The Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (adapted from Chobanian et al, 2003). 
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Table 1.4 : Classes of antihypertensive drugs, examples and possible side-effects  
 
Class Drug Possible side-effects 
Diuretics Chlorothiazide 
Hydrochlorothiazide 
Furosemide 
Torsemide 
Amiloride 
Triamterene 
 
Hypokalaemia 
Aggravation of gout 
Hyperglycaemia 
Impotence 
 
Beta blockers Atenolol 
Bisoprolol 
Propranolol 
Acebutolol 
Pendutolol 
Pindolol 
 
Aggravation of bronchial asthma 
Precipitation of cardiac failure 
Mask the impending hypoglycaemia symptoms of diabetic 
patient 
 
Calcium channel  
blockers 
Diltiazem 
Verapamil 
Amlodipine 
Felodipine 
Nicardipine 
Nisoldipine 
 
Flushing of the skin 
Headaches 
Dizziness 
Gravitational oedema 
Bradycardia 
Precipitation of cardiac failure 
 
Angiotensin  
receptor 
blockers 
Candesartan 
Irbesartan 
Losartan 
Olmesartan 
telmisartan 
Valsartan 
 
Prolong hypovolaemia caused by diuretics 
Precipitate renal failure 
Angiotensin- 
converting 
enzyme 
inhibitors 
Captopril 
Enalapril 
Lisinopril 
Perindopril 
Ramipril 
trandolapril 
Prolong hypovolaemia caused by diuretics 
Angioedema 
Dry cough 
 
Direct 
vasodilators 
Hydralazine 
Minoxidil 
 
Reflex tachycardia 
Fluid retention 
Induce autoimmune condition 
Alpha-1 
adrenergic 
blockers 
Prazosin 
Doxazosin 
Terazosin 
 
Postural hypotension 
Retrograde ejaculation of seminal fluid into bladder 
Central alpha-2 
agonist and 
centrally acting 
drugs 
Clonidine 
Methyldopa 
Reserpine 
 
 
Drowsiness 
Depression 
Salt and water retention 
 
(Adapted from Chobanian et al, 2003 and Roger et al, 2011) 
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1.4.4.1 Angiotensin-converting enzyme inhibitor 
An ACEI acts by inhibiting the activity of ACE to decrease the level of Ang II, thus 
causing vasodilation that lowers the TPR and hence the BP.  Other effects of ACEI include 
increasing BK levels, reducing sympathetic nervous system activities, and lowering 
aldosterone levels.  The ACEIs are popular among antihypertensive patient as well as CVD 
patient because in addition to the inhibition of ACE activity, they have other beneficial 
effects especially on the hearts and kidneys (Corti et al, 2001; Comini et al, 2007).  With 
the exception of captopril and lisinopril, all ACEIs used in the clinics are prodrugs that 
need to be bioactivated by the liver and each of them has different potency, plasma half-life, 
efficacy and affinity for tissue ACE (Roger et al, 2011).   
 
1.4.4.2 Vasopeptidase inhibitor  
Two of the most important vasodilators in the body are BK and NPs.  Bradykinin is 
mainly degraded by ACE (Turner and Hooper, 2002) whereas NPs are degraded primarily 
by NEP (Ruschitzka et al, 2001).  Infusion of NPs to hypertensive patient has been proven 
to be able to decrease BP by increasing natriuresis, but this method is not practical because 
NP is orally inactive (Xu et al, 2004) and the production cost is high (Corti et al, 2001).  
Thus, inhibition of ACE or NEP may become a powerful target for combating hypertension. 
However, both ACEI and NEP inhibitor (NEPI) have their drawbacks.  One of the 
weaknesses for ACEI is that ACEI is less responsive in some patients which may be due to 
when ACE is inhibited by ACEI, RAS is being activated continuously or kinins such as BK 
may be continuously metabolised by NEP (Fielitz et al, 2002; Xu et al, 2004).  Similarly, 
NEPI is less efficient in reducing BP due to its nonspecificity (Sagnella, 2002) and it also 
increases the production of a vasoconstrictor, ET-1 (Daull et al, 2007).  Although NEPI has 
25 
 
weak antihypertensive effect, it was found to be more effective than ACEI in the treatment 
of salt- and volume- dependent hypertensive rats (Pham et al, 1993).   
Since ACE and NEP have the same active site, vasopeptidase inhibitor (VPI) which 
inhibits both enzymes, may overcome their respective disadvantages (Xu et al, 2004).  
Vasopeptidase inhibitors refer to agents that can simultaneously block at least two of the 
three vasopeptidases, ACE, NEP and endothelin-converting enzyme (Ruschitzka et al, 
2001).  Among the VPIs, simultaneous inhibition of both ACE and NEP is the most 
popular treatment form and the VPI discussed here refers to ACE/NEP inhibition.  The 
overall effect of VPI is to inhibit the activity of vasopeptidases, decrease the production of 
Ang II and to potentiate the effects of NPs and BK, which leads to increased diuresis and 
vasodilation that produce BP lowering and cardioprotective effects (Xu et al, 2004).  It is 
said to have better BP reducing effect and cardioprotective effect than either ACEI or NEPI 
alone, which may due to more complete protection of kinins (Xu et al, 2004).  However, 
the main concern arises from VPI is the often fatal side-effect of angioedema which occurs 
at a higher rate than its counterparts (Sagnella, 2002).  The safety issue regarding 
angioedema is the main reason that led to the decision of Food and Drug Administration 
(FDA) to disapprove the popular VPI omapatrilat (Song and White, 2001).  Since then, 
development of potential VPIs is limited.     
 
1.4.4.3 Combination therapy 
When a single drug fails to achieve its goal, usually combination therapy will be 
considered.  Combination therapy for hypertension involves combined use of two or more 
different classes of antihypertensive drugs (Gradman et al, 2010).  Combination therapy 
uses the synergistic effect of each component and is considered to be more effective in 
lowering BP than monotherapy, and with less dose-dependent side-effects (Gradman et al, 
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2010).  Hypertensive patients who are receiving combination therapy take either two or 
more different medications separately or take them in fixed-drug combination form 
(Rosenthal and Gavras, 2006).  Fixed-drug combination involves fewer pills, better 
tolerability, lower cost, increased convenience and it is also faster to achieve the BP 
reduction target but the main disadvantages are loss of flexibility and unclear causes of 
side-effects (Rosenthal and Gavras, 2006).  Examples of combination therapies that are 
available in market include diuretic + BB, ACEI + diuretic, ACEI + CCB and CCB + BB 
(Rosenthal and Gavras, 2006).     
 
1.4.4.4 Vaccine for hypertension 
Since the success rate for managing hypertension is low and the main regulatory 
mechanism of BP is the RAS, an active immunisation strategy against Ang II has been 
mooted and it is now in phase II clinical trial (Ambuhl et al, 2007).  Immunisation has 
obvious benefits in that it does not require daily dosing because of the longer-lasting effect.  
This vaccine, CYT006-AngQb (AngQb), is a conjugate vaccine which uses Ang II linked 
to a recombinant virus-like particle (Ambuhl et al, 2007).  Several studies have shown that 
this vaccine is safe with no severe side-effect, has 100% immune response with half-life 
about 4 months after the third booster dose, is reversible and the BP lowering effect is 
similar with that of low-dose direct renin inhibitor (Ambuhl et al, 2007; Tissot et al, 2008). 
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1.5 Complementary and alternative medicine  
1.5.1 Overview 
Complementary and alternative medicine (CAM) represents groups of medical 
practice that fall outside of conventional therapies, and their efficacies and safeties may not 
have been scientifically proven (Mainardi et al, 2009).  Examples of CAM that are being 
commonly practised are yoga, meditation, acupuncture, herbal and supplementary medicine, 
massage, chiropractic and spiritual healing (Miller et al, 2004).  In the United States of 
America, there appears to be a tendency for patients to seek CAM practitioners for 
treatment than to look for conventional physicians (Frishman et al, 2009).  In addition, 
according to the World Health Organisation (WHO), 80% of the world population use 
plant-derived medicine (Gurib-Fakim, 2006) and among the traditional medicine from 
various countries, traditional Chinese medicine (TCM) seems to be growing rapidly 
(Davidson et al, 2003).  The TCM is used either as an adjunct or an alternative to Western 
medicine (Davidson et al, 2003).   
Among CAM, herbal and supplemental therapy is growing at the fastest speed 
(Buck and Michel, 2000).  In fact many of the commercially available drugs are derived 
from herbs (Frishman et al, 2009) such as ephedrine from Ephedra sinica (Ma Huang) (Lee, 
2011), digitoxin from Digitalis purpurea (foxglove) (Warren, 1986), salicin (source of 
aspirin) from Salix alba (willow bark)(Meier et al, 1988) and reserpine from Rauwolfia 
serpentine (snakeroot) (Cieri, 1998).  The routes of administration of herbs include oral, 
nasal, topical, rectal, bathe and subcutaneous or intramuscular injection (Gurib-Fakim, 
2006).  However, several problems are encountered especially when using herbs that are 
without the approval of FDA including drug safety and standardisation of preparation 
(Valli and Giardina, 2002).   
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1.5.2 Herb-drug interactions 
Herbs, although being natural, are not without side-effects after consuming.  There 
are always misconceptions that herbs are safe without side-effects and herbs, are panacea 
and the efficacies of herbs can be obtained over a wide-range of doses (Chang, 2000).  
Indeed, concurrent use of medicinal herbs with drugs may produce the same effect, 
magnify or even counteract the effect of drugs and drugs that are effective at one dose can 
become toxic at another dose (Fugh-Berman, 2000).  Many reports regarding the side-
effects of concurrent use of herbs with drugs are well documented which include increased 
risk of bleeding between anticoagulants (e.g. warfarin) and garlic, ginkgo, ginseng or dong 
quai (Evans, 2000); increased BP between ACEIs and St John‘s wort (Buck and Michel, 
2000); decreased antidepressant effect between antidepressants and yohimbine (Kearney et 
al, 2010); increased risk of toxicity between BBs, decongestants and Ma Huang (White et 
al, 1997) and also increased sedation between central nervous system depressants and 
valerian (Buck and Michel, 2000).   
Extensive studies on herbs of different pharmacological effects are being explored 
and carried out.  These comprise of antidiabetic, anticancer, antiulcer, lipids lowering as 
well as the antihypertensive effects.  Examples of medicinal herbs that are scientifically 
shown to be effective in treating hypertension are Rauwolfia serpentina, Stephania 
tetrandra, Lingusticum wallichii and Uncaria rhynchophylla (Frishman et al, 2009).  
Different modes of antihypertensive actions have also been found from medicinal herbs and 
some of the findings are listed in Table 1.5. 
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Modes of 
action 
Medicinal plants 
(Common name) 
Parts of 
plants 
Solvents References 
Diuretics Orthosiphon 
stamineus 
(Cat‘s whiskers) 
Coriandrum sativum 
(Yuen sai)  
Bidens odorata  
(Mozote blanco) 
Tropaeolum majus 
(Chaguinha) 
Spilanthes acmella 
(Akkirakaran) 
Lepidium sativum 
(Hab arachad) 
Leaves 
 
 
Seeds 
 
Aerial 
parts 
Leaves 
 
Flowers 
 
Seeds 
Aqueous 
 
 
Aqueous 
 
Aqueous 
 
Hydroethanol 
 
Aqueous 
 
Aqueous 
(Adam et al, 2009) 
 
 
(Aissaoui et al, 2008) 
 
(Camargo et al, 2004) 
 
(Gasparotto et al, 2009) 
 
(Ratnasooriya et al, 2004) 
 
(Maghrani et al, 2005) 
 
 
Calcium 
channel 
blockers 
Laelia autumnalis 
(Orquidea) 
Laelia anceps 
 
Valeriana officinalis 
(Valerian) 
Hibiscus sabdariffa 
(Sour tea) 
 
Flowers 
 
Roots 
 
Roots 
 
Calyces 
Methanol 
 
Methanol 
 
Ethanol, aqueous 
 
Methanol 
(Vergara-Galicia et al, 
2008) 
(Vergara-Galicia et al, 
2010) 
(Circosta et al, 2007) 
 
(Ajay et al, 2007) 
Angiotensin- 
converting 
enzyme 
inhibitors 
Clerodendron 
trichotomum 
Rabdosia coetsa 
 
Cuscuta japonica 
 
Tribulus terrestris 
 
Musanga 
cecropioides 
(Umbrella tree) 
 
Stems 
 
Whole 
plant 
Seeds 
 
Fruits 
 
Stems 
Ethyl acetate 
 
Ethyl acetate 
 
Ethyl acetate 
 
Aqueous 
 
Aqueous 
(Kang et al, 2003) 
 
(Li et al, 2008) 
 
(Oh et al, 2002) 
 
(Sharifi et al, 2003) 
 
(Adeneye et al, 2006) 
Angiotensin 
receptor 
blockers 
Salvia elegans 
(Mirto) 
Bocconia frutescens 
 
Citrus limetta 
 
Astragalus 
complanatus 
Hippophae 
rhamnoides 
(Shaji) 
 
Aerial 
parts 
Roots 
 
Leaves 
 
Seeds 
 
Seeds 
Hydroethanol 
 
Methanol/ 
dichloromethane 
Aqueous 
 
Total flavonoid fraction 
in distilled water 
Total flavones in distilled 
water 
(Jimenez-Ferrer et al, 
2010) 
(Caballero-George et al, 
2003) 
(Perez et al, 2010) 
 
(Xue et al, 2008) 
 
(Pang et al, 2008) 
 
 
 
 
 
 
Table 1.5 : Examples of antihypertensive medicinal herbs with different types of 
mechanisms of action. 
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‗Table 1.5, continued‘ 
Potassium 
channel 
activation 
Brillantaisia nitens 
 
Valeriana wallichii 
(Indian valerian) 
Ulmus macrocarpa 
 
Leaves 
 
Rhizomes 
 
Roots 
Methylene 
chloride/methanol 
Chloroform, aqueous 
 
Ethanol 
(Dimo et al, 2007) 
 
(Gilani et al, 2005) 
 
(Oh et al, 2008) 
Sympatholegic 
activities 
Jacaranda minosaefolia 
(Jacaranda) 
Eugenia uniflora 
(Pitanga) 
Rhodiola sacra 
(Plateau ginseng) 
 
Leaves 
 
Leaves 
 
Roots 
Hydromethanol 
 
Aqueous 
 
Aqueous 
(Nicasio and Meckes, 
2005) 
(Consolini et al, 1999) 
 
(Shih et al, 2008) 
Nitric oxide 
and 
endothelium 
dependant 
vasodilation 
Mansoa hirsute 
 
Maytenus ilicifolia 
 
Fritillaria ussuriensis 
(Beimu) 
Geum japonicum 
 
 
Leaves 
 
Leaves 
 
Bulbs 
 
Whole plant 
Ethanol 
 
Ethanol 
 
Aqueous 
 
Butanol 
 
(Campana et al, 2009) 
 
(Crestani et al, 2009) 
 
(Kang et al, 2002) 
 
(Xie et al, 2007) 
 
 
    
1.6 Methods and techniques 
1.6.1 Fractionation, purification and isolation of natural products 
Natural products, especially herbs, have been sources of therapeutic agents since 
ancient times (Spainhour, 2005).  Recently, in a period between 1981 to 2002, it was found 
that among the 74 synthetic drugs approved for the treatment of hypertension, 48 of them 
were found to be of plant origin (Newman et al, 2003).   
The methods of consumption that traditionally practised such as chewing the raw 
plants or boiling the plants have several weaknesses such as variation in the amount of 
active compounds, reaction among other compounds that coexist with the bioactive 
compounds and change or loss of bioactivity due to variation in collection, processing and 
storage of the plant (Colegate and Molyneux, 2008).  Scientific ways to obtain bioactive 
compounds from natural products are needed and involve detection and screening, isolation 
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and purification, and structure identification of bioactive compounds (Spainhour, 2005; 
Colegate and Molyneux, 2008). 
Detection and screening of potential bioactive plants are done by various in vitro as 
well as in vivo assays.  After identifying certain bioactive plants, the next step is isolation 
and purification which involves various techniques and technologies.  The first step is 
usually extraction of the plant by using solvents with different polarities.  The next step 
involves further solvent partition and extensive chromatography methods by considering 
acidity, polarity and molecular size of the compounds (Colegate and Molyneux, 2008).  
These involve techniques such as solid-phase extraction, high performance liquid 
chromatography (HPLC), thin layer chromatography (TLC), counter current 
chromatography, desalting and ion exchange chromatography (Spainhour, 2005).  Today, 
the last step structural elucidation of bioactive compounds uses advanced technologies and 
techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry 
(MS), ultraviolet (UV)/visible and infrared absorption spectroscopy and also ‗hyphenated‘ 
technologies such as HPLC-MS, HPLC-NMR and MS-MS (Spainhour, 2005; Colegate and 
Molyneux, 2008).  
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1.6.2 Blood pressure measurement methods 
Measurement of BP in laboratory rats can be divided into direct and indirect 
methods.  Both of these methods have their advantages and disadvantages and the choice of 
method depends on the objectives of the study (Kurtz et al, 2005).  
In indirect method, it is non-invasive which means no surgical procedure is required.  
The most common indirect method is the use of a cuff in which changes in the blood flow 
in a tail or limb is detected by the occlusion or release of the cuff (Kurtz et al, 2005).  The 
advantages of this method are: (1) non-invasive; (2) less expensive compared to other 
method such as telemetry; and (3) can be used to study changes in BP in large groups of 
animals over a short or long period of time (Van Vliet et al, 2000; Kurtz et al, 2005).  In 
contrast, the main disadvantage is that this method requires physical restraint and heating 
that poses stress to the animal (Irvine et al, 1997).  This method is thus advised to be used 
in study in which large BP difference is expected (Gross and Luft, 2003).  
In direct method, it is invasive and involves surgical procedure.  A sensor device is 
implanted into the arterial system in rat to measure the arterial BP.  There are three 
common types of sensing devices: fluid-filled catheters, transducer-tipped catheters and 
radiotelemetries (Van Vliet et al, 2000).  Fluid-filled catheter is the oldest and the most 
widely used direct method.  It uses a heparin-filled catheter to be inserted into a major 
artery of rat while the other end of the catheter is connected to a BP transducer.  This 
method can be used in acute as well as chronic measurement of BP in animals.  The main 
advantage of this fluid-filled catheter method is that it produces accurate and reliable 
readings and permits infusion of various experimental agents (Kurtz et al, 2005).  However, 
this method imposes some stress to animals because the animals are not free-moving and 
the presence of clotting around the catheter tips can affect the BP readings (Kurtz et al, 
2005).  Moreover, there is also a risk of infection because it involves surgical procedure.  
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Although transducer-tipped catheter is more sensitive, it is more expensive and only 
suitable for short term study (Van Vliet et al, 2000).  The method of radiotelemetry can be 
used in wider areas of studies.  Radiotelemetry uses a BP sensor (radiotelemetric probe) 
which is implanted in the animal and adopts an electrical device to receive and process the 
signal.  The advantages include: (1) measures BP of free moving conscious animals; (2) 
causes less stress as no restraint of animal is required; (3) less labor intensive; (4) more 
efficient, convenience and reliable; (5) measures BP for a longer duration compared to the 
catheterised method; (6) no anesthesia is involved during BP measurement; (7) can 
measure BP around the clock (Mills et al, 2000; Van Vliet et al, 2000).  The main problem 
arises from radiotelemetry is its high cost, requires more technical skills and also has the 
risk of infection (Kurtz et al, 2005).       
 
1.6.3 In vitro vascular tension studies 
To study the pharmacological effect of vasoactive agents on smooth muscles and 
their drug-receptor interaction, strips or ring segments of arteries isolated from laboratory 
animals such as rats and rabbits are used (Furchgott and Bhadrakom, 1953).  In this in vitro 
method, the strips are removed from laboratory animals and mounted with stainless steel S-
hooks in physiological solutions (eg. Krebs-bicarbonate solution) bubbled with 95% 
oxygen and 5% carbon dioxide in organ chambers (Furchgott and Bhadrakom, 1953).  The 
strips or ring segments of arteries are attached to force transducer to record the changes in 
tension in arteries to various vasoactive drugs (Gonzales et al, 2000).  One of the most 
popular findings using this in vitro vascular tension method was the discovery of 
endothelial-derived hyperpolarising factor which involves the release of NO that causes the 
relaxation of VSM (Furchgott, 1999).  Earlier studies using this method have shown that 
epinephrine, norepinephrine and ACh caused vasocontraction whereas sodium nitrite 
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caused vasorelaxation (Furchgott and Bhadrakom, 1953), but later studies proved that ACh 
is a vasorelaxant agent rather than a vasoconstrictor agent (Furchgott, 1999).   
 
1.6.4 Laboratory animals 
Spontaneously hypertensive (SHR) rat is the most widely used animal model for 
hypertension.  It belongs to the phenotype-driven genetic model of hypertension (Lerman et 
al, 2005).  The SHR strain was obtained by selective breeding of spontaneously 
hypertensive Wistar-Kyoto (WKY) male rat with relatively higher BP female rat (Okamoto 
and Aoki, 1963).  This strain of rat is widely used in hypertension studies because the 
incidence of hypertension is 100%, it is sensitive to various antihypertensive agents which 
are also effective in human (Yamori and Okamoto, 1973) and it presents hypertensive 
complications (Yamori and Okamoto, 1973).  Other than that, stroke prone SHR and 
arteriolipidosis-prone rats were developed from SHR as a model for stoke and 
atherosclerosis (Yamori, 1978).   
The most commonly used control strain for SHR rat is WKY rat (Johnson et al, 
1992).  Initially it was thought that all WKY rats constituted a single inbred strain.  Later 
studies showed that there was a great biological variability among WKY rats themselves 
and also between SHR and WKY rats (Kurtz et al, 1989; Johnson et al, 1992).  Although 
these findings were discovered, WKY rat is still extensively used as a control for SHR 
because SHR was derived from WKY rat (Kurtz and Morris, 1987).  
Another strain of rats that are widely studies and extensively used in various 
research fields are Sprague-Dawley (SD) rats.  This strain was produced by the Sprague-
Dawley Company, Madison, Wisconsin, in 1925.  The main advantages of SD rat are its 
docile character that makes it easier to be handled and also its excellent reproductive 
performance.   
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1.6.5 Nuclear magnetic resonance spectroscopy and mass spectrometer 
One of the most powerful instruments to obtain the structure of an organic 
compound is NMR spectroscopy.  This instrument uses a principle in which when a 
compound containing nuclei such as 
1
H
 
or 
13
C is put in a strong magnetic field and 
simultaneously irradiated with certain electromagnetic energy; the absorption of energy is 
quantized by the NMR spectroscopy and displayed as NMR spectra which can be either 1 
dimensional (D) or 2D as well.  The most common nuclei used in NMR spectroscopy are 
1
H and 
13
C.  
Nuclear magnetic resonance spectroscopy usually works together with MS for a 
better understanding of the molecule.  The MS provides the molecular weight (MW) of a 
certain molecule whereas NMR spectroscopy tells the connectivity between atoms in a 
molecule.  In comparison, NMR spectroscopy has an advantage over MS that it is not 
destructive (the sample can be recovered) although more amount of sample is needed for 
NMR spectroscopy.     
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1.6.6 In vitro assay of angiotensin-converting enzyme activity  
Inhibition of ACE has been an effective therapeutic approach for hypertension and 
ACE inhibitory compounds can be found in some plants.  There are researches carrying out 
to search for potential ACE inhibitory compounds from plants (Hansen et al, 1995; Duncan 
et al, 1999; Lacaille et al, 2001).  Many methods have been used to study the potential 
ACE inhibitory activities from compounds isolated from plants or crude extracts from 
plants.  These methods use spectrophotometry, fluorometry, HPLC or radiochemistry (Lam 
le et al, 2007).  
 In 1991, a new method, based on the cleavage of chromophore- and fluorophore- 
labeled substrate, dansyltriglycine by ACE into dansylglycine, which was measured by 
HPLC, was introduced (Elbl and Wagner, 1991).  From the past times until now, many 
methods, either modified or with new principles are introduced and adopted in many 
studies.  For example, in 2005, a cost-effective and high throughput method with the 
absorbance of final product measured by using microtitre plate reader was introduced 
(Serra et al, 2005).  Then, a method which used a new substrate known as                          
3-hydroxybutyrylglycyl-glycyl-glycine, was claimed to be more sensitive, rapid and 
accurate than conventional method (Lam le et al, 2007).  Later that, a rapid, sensitive, high-
throughput and advanced colorimetric assay to measure hippuric acid (HA) has also been 
created (Jimsheena and Gowda, 2009).  
 Although there are plenty of methods to measure ACE activity, the colorimetric 
assay introduced by Cushman and Cheong by using synthetic peptide, hippuryl-L-histidyl-
L-leucine (HHL) as a substrate is the most popular (Jimsheena and Gowda, 2009).  In this 
method, HHL is hydrolysed by ACE to form HA and histidyl-leucine (HL).  The amount of 
HA produced is proportional to the ACE activity which are then extracted and measured by 
spectrophotometer at 228 nm (Cushman and Cheung, 1971).  This method has some 
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 ACE 
drawbacks: it is time-consuming, unhydrolysed HHL may be extracted and this method is 
not suitable for high-throughput screening (Jimsheena and Gowda, 2009). 
 Since the method by Cushman and Cheung, 1971 has several disadvantages; a 
method which based on colorimetric determination of HA with reduced interference has 
been developed (Hurst and Lovell-Smith, 1981).  In this method, no extraction of HA is 
required because the HA produced reacts directly with the colorimetric reagent, cyanuric 
chloride (2,4,6-trichloro-s-triazine) in dioxane.  This reaction produces a coloured complex 
that can be quantified from its absorbance at 382 nm (Hayakari et al, 1978).  The principle 
for this method is shown in Figure 1.6 (Hoe et al, 2007). 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hippuryl-L-histidyl-
L-leucine (HHL) 
Histidyl-
leucine (HL) 
Hippuric acid 
(HA) 
+ 
 + 
Cyanuric chloride/ 
dioxane 
Coloured complex 
Figure 1.6 : The principle for the measurement of angiotensin-converting enzyme 
activity by a colorimetric assay (adapted from Hurst and Lovell-Smith, 1981).  
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1.6.7 In vitro assay of neutral endopeptidase activity  
In search of potential ACE inhibitory compounds from plants, NEP inhibitory 
compounds, although less popular, can be found in some plants as well (Kiss et al, 2005).  
Methods with the principles of radiochemistry, colorimetic, enzyme-linked immunosorbent 
assay and the most popular fluorometric method have been used to study the NEP activities 
in tissues or sera (Yandle et al, 1992; Tudoric et al, 2000).  The synthetic substrates that are 
being used include glutaryl-Ala-Ala-Phe-amidomethylcoumarin(Yandle et al, 1992), N-
dansyl-Ala-Gly-D-nitro-Phe-Gly (DAGNPG) (Jiang et al, 2004) and Suc-L-Ala-L-Ala-Phe-
7-amino-4-methylcoumarin (SAAP-AMC) (Kiss et al, 2005). 
Until now, methods to measure the NEP activities have been modified and 
transferred to screen for potential NEP inhibitory compounds from plants.  For example, a 
two-step assay based on Bormann and Melzig (Bormann and Melzig, 2000) has been 
widely used by Kiss A (Kiss et al, 2005; Kiss et al, 2006; Kiss et al, 2008).  In this two-
step assay, the first reaction is initiated by the addition of NEP to the substrate SAAP-AMC 
to form Phe-7-amino-4-methylcoumarin (P-AMC).  The second reaction is the action of 
leucine aminopeptidase (APN) on P-AMC to form 7-amino-4-methylcoumarin (AMC) 
which is fluorescence and measured by spectrofluorometer at λexcitation = 355 nm and λemission 
= 460 nm.  The two-step reaction is shown in Figure 1.7. 
 
 
 
 
 
 
 
 
 
 
SAAP-AMC P-AMC AMC 
(fluoresce
nce) 
NEP APN 
Figure 1.7 : The two-step reaction that finally produces fluorescence 7-amino-4-
methylcoumarin (adapted from Bormann and Melzig, 2000).   
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1.6.8 Effects of proteases on plant extract 
 Proteases are enzymes that hydrolyse proteins and they are involved in many 
physiological reactions in the human body.  One of the reactions is the digestion process 
wherein some of the important proteases are pepsin, trypsin and chymotrypsin (Guyton and 
Hall
2
, 2006).  These enzymes may change the actions or functions of the compounds that 
taken into the body.   
Study by Hoe et al, 2007 postulated that the putative hypotensive agents in this 
plant extract seem to be peptidal substances in nature.  This aspect is further studied by 
using NMR spectroscopy and HPLC-MS and also by the effects of these three proteases on 
ACE inhibitory activities of the plant extract.  Loss of ACE inhibitory activity of plant 
extract may show that the extract is degraded by proteases and it is most probably a kind of 
protein.        
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1.7 Plant material 
1.7.1 Family Asteraceae/ Compositae 
Family Asteraceae or Compositae comprises of herbs or shrubs, but are rarely trees 
or vines (Mbagwu et al, 2009).  Their leaves are simple, opposite or alternate but rarely 
compound (Mbagwu et al, 2009).  There are involucres to support the flower heads and the 
flowers have ray florets at the margin and disc florets at the central (Mbagwu et al, 2009).  
Most members of Asteraceae or Compositae undergo asexual reproduction by seed (Noyes, 
2007).  Family Asteraceae comprises of 1,600 genera and 23,000 species is the largest 
family of flowering plants (Gao et al, 2010).  This family is widely distributed on all 
continents except Antarctica.   
Asteraceae has a wide range of uses such as in medicine, ornament and economy as 
well (Gao et al, 2010).  In medical application, Artemisia annua which contains 
antimalarial compound, artemisinin, has been listed in the Chinese Pharmacopoeia to treat 
fevers such as malaria (Mueller et al, 2000).  It is also found that Saussurea involucrate, 
listed in the Chinese Pharmacopoeia, has anticancer, anti-inflammation and free radical 
scavenging activities (Wu et al, 2009).  Gynura procumbens (G. procumbens), which will 
be discussed later is also popular among traditional medicine. 
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1.7.2 Gynura procumbens 
 
 
 
Kingdom Plantae 
Division Magnoliophyta 
Class Magnoliopsida 
Order Asterales 
Family Asteraceae or Compositae 
Genus Gynura 
Species procumbens 
 
(adapted from Botanica Sistematica, 2009) 
 
 
Gynura procumbens (Lour.) Merr. is a weak climbing or scrambling perennial herb.  
In Malaysia, its common names are akar sebiak, sambung nyawa, daun dewa, kelemai 
merah, acham akar and dewa raja.  Its stems can grow up to 6 meters long, with smooth or 
sparsely pubescent.  Young stems are green and become light purple with green spots when 
mature.  The leaves are almost oval-shaped with size of 3-10cm X 0.5-3cm.  The lower 
surfaces of the leaves are purplish.  Gynura procumbens can be found in Central and 
Western Africa, Southeast Asia, China and Papua New Guinea.  This plant is fast growing 
and easy to breed by using stem cuttings (Globinmed, 2010).  Figure 1.8 shows the photo 
of G. procumbens planted in Kuala Kangsar, Perak, Malaysia. 
In folk medicine, the plant is used for treating kidney diseases, fever and rashes 
(Perry, 1980) and for hypertension.  Scientifically, G. procumbens is found to have the 
following properties: 
1. Antihypertensive (Lam et al, 1998; Hoe and Lam, 2005) 
2. Anti-ulcer (Mahmood et al, 2010) 
3. Anti-oxidant (Puangpronpitag et al, 2010) 
4. Antidiabetic and antihyperlipidemic (Zhang and Tan2, 2000) 
Table 1.6 : Taxonomy of Gynura procumbens. 
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Figure 1.8 : Gynura procumbens (Lour.) Merr. 
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1.8 Research objectives 
 Hypertension is one of the major health problems worldwide and most of the 
conventional treatments have side-effects.  Searching of potential antihypertensive plants 
has been an alternative in belief that the plant, being natural may have lesser side-effects.  
Previous studies from our laboratory have shown that a partially purified fraction (FA-I) 
from final aqueous fraction (FA), from G. procumbens possesses antihypertensive effect by 
inhibiting ACE (Hoe et al, 2007) and blocking calcium channels (Hoe et al, 2011).  The 
present study was designed with the following objectives: 
1. To explore the effects and mechanism of FA-I on Ang II-induced contraction of 
aortic rings as well as hypotensive and vasodilatory effects of BK 
2.  To test the dual ACE/NEP inhibitory activities of FA-I and its subfractions 
3. To study the acute oral antihypertensive effects of FA-I 
4. To characterise bioactive FA-I subfractions 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Plant material 
Whole plants of G. procumbens were collected from Peninsular Malaysia.  Three 
voucher specimens (KLU 047690, KLU 047691 and KLU 047692) have been deposited in 
the Herbarium at Rimba Ilmu, University of Malaya.  The photo below shows one of the 
voucher specimens with herbarium number KLU 047690. 
 
 
 
 
 
 
 
 
 
 
2.1.2 Animals 
Adult male SD, SHR and WKY rats, weighing between 250-320 g, were obtained 
from the Experimental Animal Care unit, University of Malaya and kept under standard 
conditions.  Normal commercial rat chow (Gold Coin Animal Feed, Malaysia) and tap 
water were provided ad libitum.  All studies on experimental animals have been conducted 
under protocols reviewed and approved by the Animal Ethics Committee, University of 
Malaya Medical Center (Ethics Reference Number: FIS 14/ 10/ 2009/ 0112/ PTF (R)).  
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2.1.3 Chemicals and reagents 
 All the chemicals and reagents used were of analytical grade unless otherwise stated: 
Ang I (AnaSpec, INC, USA), heparin sodium 5,000 I.U. (LEO Pharmaceutical Products 
Ltd., Ballerup, Denmark), Sephadex
TM
 LH-20 (Amersham Bioscience AB, Uppsala, 
Sweden), sodium hydroxide (NaOH) (Fisher Scientific, U.K.) and Nembutal sodium 
pentobarbitone (CEVA Sante Animale, Libourne, France).     
   Chemicals and reagents from Merck KGaA, Darmstadt, Germany are Ang II, BK, 
boric acid (H3BO3), calcium chloride (CaCl2), glucose, indomethacin, magnesium sulphate 
(MgSO4), NEP from porcine kidney, ninhydrin, phosphoramidon, potassium dihydrogen 
phosphate (KH2PO4), potassium chloride (KCl), silica gel 60 F254 TLC aluminium sheets, 
sodium bicarbonate (NaHCO3), sodium chloride (NaCl) and 1,4-dioxan, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).   
Apart from that, ACh chloride, APN, bovine chymotrypsin, bovine trypsin, 
cyanuric chloride, HA, HHL acetate, hydrochloric acid (HCl), N
ω
-nitro-L-arginine methyl 
ester (L-NAME), pepsin from porcine gastric mucous membrane, phenylephrine (PE) 
hydrochloride, rabbit ACE and SAAP-AMC were produced by Sigma-Aldrich Co., St 
Louis, MO, USA.  The solvents acetic acid, acetone, ethanol, ethyl acetate, hexane, 
methanol and n-butanol are from R & M Marketing, Essex, U.K. 
 Rat chows were purchase from Gold Coin Feedmills (M) Sdn Bhd, Selangor, 
Malaysia. 
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2.1.4  Equipment 
The main equipments used in this study were: 
Vacuum evaporation system consisting of a rotary evaporator, an oil bath (model 
OSB-2000) and an aspirator (model A-1000S ) from Eyela Tokyo Rikakikai Co., Ltd., 
Japan, with a low temperature circulator (model WCR-P8) from Daihan Scientific Co., Ltd., 
Seoul, Korea. 
Digital physiographic recording system (PowerLab, ADInstruments Pty. Ltd., 
Australia) consisting of a PowerLab Data Acquisition System (model ML866), a 
BridgeAmp (model ML224), a BioAmp (model ML136), a NIBP controller (model 
ML125), a force transducer (model MLT050/D) and a BP transducer (model MLT0380/D) 
that is controlled by a HP personal computer (model HPL1908w) loaded with the 
PowerLab Chart Version 5.0 Software. 
Other equipments include a chromatography column (2.5 cm, i.d. x 75 cm, height), 
fraction collector (Bio-Rad 2100, Bio-Rad Laboratories, U.S.A.), reagent spray (Camag, 
Switzerland), viewing cabinet (Chromato-vue CC-10, U.K.) combined with multi-band 
254/365nm lamp (UVGL-58), micro tube pump (Eyela MP-3, Japan), NMR spectrometer 
400 MHz (JEOL, JEOL Ltd, Japan), microprocessor-based bench-top pH meter (Hanna
®
 
pH 211, Hanna
®
 Instruments, U.S.A.), centrifuge (Jouan CR 312, American Laboratory 
Trading, Inc, U.S.A.), UV-VIS spectrophotometer (Model UV mini 1240, Shimadzu, 
Germany), spectrofluorometer (Model Fluoroskan Ascent FL, Thermo Scientific, U.K.).   
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2.2  Extraction and fractionation of Gynura procumbens leaves 
 The protocols for extraction and fractionation follow the method used by Hoe, 2007 
(Figure 2.1).  Briefly, leaves from fresh G. procumbens were cleaned and dried in an oven 
at 40
o
C and then ground to powder.  They were then processed through the following steps 
in a sequential manner ie extract in 96% ethanol and 80% aqueous ethanol, defatted in 
hexane and fractionated by water-saturated butanol to obtain the final aqueous fraction 
(FA), which was then passed through a column containing Sephadex LH-20 gel (Appendix 
A) to obtain FA-I fraction (Figure 2.1).  The FA-I fraction was subjected to preparative 
TLC (Appendix B) resulted in several FA-I subfractions (FA-Ia – FA-Ie) that were 
revealed by ninhydrin reagent (Appendix C).  Using a bioassay guided protocol, the FA-I 
subfractions that were tested for positive bioactivities were subsequently sent for 
characterisation by 
1
H NMR 400 MHz spectrometer (JEOL, Japan).  The FA-Ia subfraction 
was analysed more extensively by 
13
C NMR 100 MHz, 2D distortionless enhancement by 
polarisation transfer (DEPT) NMR 100 MHz, infrared spectroscopy and LCMS.  
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1. Reconstituted in 80% aqueous 
ethanol 
2. Defatted with hexane 
Figure 2.1 : Extraction and fractionation of Gynura procumbens that finally produce the 
FA-I subfractions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1. Cleaned, dried and ground 
2. Extracted with 96% ethanol 
3. Evaporated in vacuo 
Butanol extract 
FA-I 
Sephadex LH-20 column chromatography 
FA-I subfractions 
Preparative thin layer chromatography 
G. procumbens leaves 
Crude ethanol extract 
Aqueous ethanol extract Hexane extract 
 
      1. Evaporated in vacuo to remove ethanol 
2. Aqueous solution was filtered out 
Fractionated with water-saturated n-butanol 
 
Final aqueous extract (FA) 
Aqueous extract Ethanol extract 
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2.3 In vitro vascular tension studies  
   The effects of FA-I on blood vessels were studied using in vitro techniques on 
isolated rat thoracic aorta. 
 
2.3.1 Preparation of rat aortic rings 
The descending thoracic aorta was removed from male SD rats and mounted in ice-
cold oxygenated Krebs-Henseleit (K-H) solution (Appendix D).  The isometric contractile 
force of the aorta was recorded by the PowerLab computer system.  The procedures for 
preparation of rat aortic rings are presented below while Figure 2.2 shows a photograph of 
an aortic ring in an organ bath chamber.   
For some preparations, the endothelial layer of aortic ring was mechanically 
removed by inserting a pair of fine forceps into the lumen and gently rotating the aorta 
around the forceps.  These endothelium-denuded rings were similarly equilibrated in organ 
bath for 60 min.  The success of the endothelial denudation was tested by precontracting 
the rings with 1.0 x 10
-6
 M PE and observing the response to 1.0 x 10
-5
 M ACh.  A lack of 
any relaxation of the PE-precontracted rings indicated that the endothelium was 
satisfactorily removed whilst relaxation of at least 70% of the PE-induced contraction 
showed that the endothelial layer was still present.  The instructions for the preparation of 
aortic rings are shown below: 
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Lower hook 
Upper hook connected 
to a force transducer 
Organ bath with  
10 ml K-H solution 
Aortic ring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rat sacrificed by decapitation and the descending thoracic aorta taken and placed 
in a petri dish containing ice-cold oxygenated K-H solution. 
The connective tissues and fats from aorta removed and cut into rings (1 – 3 mm in 
length). 
The aortic ring mounted in an organ bath containing 10 ml K-H solution with 2 
stainless-steel hooks; the lower hook fixed to the bottom of the bath whereas the 
upper hook connected to a force-displacement transducer. 
The bath solution maintained at 37 
o
C and bubbled continuously with 95% oxygen 
and 5% carbon dioxide gas mixture. 
Each ring subjected to a resting tension of 1 g and allowed to equilibrate for 60 min 
while being rinsed every 15 min.  During the equilibration period, the rings 
stimulated at least three times with 6 x 10
-2 
M KCl until a reproducible contractile 
response obtained. 
 
Figure 2.2 : The aortic ring was mounted in an organ bath containing 10 ml Krebs-
Henseleit solution with the lower hook being fixed to the bottom of the bath whereas the 
upper hook is connected to a force-displacement transducer connected to a digital 
physiographic setup. 
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2.3.2 Effects of FA-I pretreatment on angiotensin I-induced contraction 
Endothelium-intact (n = 6) and -denuded aortic rings (n = 6) were preincubated for 
20 min in the absence or presence of FA-I (final concentration: 1.0 x 10
-4 
and 1.0 x 10
-3
 
g/ml) (with reference to Hoe, 2007).  After the incubation period, contraction of the rings 
was evoked by adding cumulative concentrations of Ang I (1 x 10
-8.5
 M - 1 x 10
-6 
M) and 
their responses in the absence or presence of FA-I were recorded.    
 
2.3.3 Effects of FA-I pretreatment on angiotensin II-induced contraction 
Endothelium-intact (n = 6) and -denuded aortic rings (n = 6) were preincubated for 
20 min in the absence or presence of FA-I (final concentration: 1.0 x 10
-4 
and 1.0 x 10
-3
 
g/ml).  After the incubation period, contraction of the rings was evoked by adding 
cumulative concentrations of Ang II (1 x 10
-8.5
 M – 1 x 10-6 M) and their responses in the 
absence or presence of FA-I were recorded.    
 
2.3.4 Effects of FA-I pretreatment on angiotensin II-induced contraction of aortic 
rings in the presence of N
ω
-nitro-L-arginine methyl ester or indomethacin 
 
To study the involvement of endothelium in the response to Ang II brought by FA-I, 
endothelium-intact rings (n = 6) were preincubated for 20 min with or without FA-I (final 
concentration: 1.0 x 10
-4 
and 1.0 x 10
-3
 g/ml) and indomethacin (final concentration: 10 
µM), a non-selective COX inhibitor or L-NAME (final concentration: 0.1 µM), an eNOS 
inhibitor, and followed by the cumulative additions of Ang II. 
 
2.3.5 Effects of FA-I pretreatment on bradykinin-induced relaxation of 
phenylephrine-precontracted aortic rings 
 
After the equilibration period, intact aortic rings (n = 8) were precontracted again 
with PE (1.0 x 10
-6
 M).  The contractions of aortic rings to PE were allowed to reach a 
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plateau before the cumulative addition of BK (1.0 x 10
-11 
M – 1.0 x 10-6 M).  The relaxation 
responses of PE-precontracted aortic rings to the cumulative additions of BK were 
determined in the presence or absence of pretreatment with FA-I (final concentration: 1.0 x 
10
-4 
and 1.0 x 10
-3
 g/ml) 20 min before the sequential additions of PE and BK. 
 
2.4 Effects of FA-I on the action of bradykinin on mean arterial pressure and 
heart rate of rats  
 
The BP was recorded by a pressure transducer connected to a PowerLab setup.  The 
procedures for direct BP measurement in rat are shown as follows:  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
In this method, heparinised saline (10 U/ml) was used to prevent blood coagulation 
and the FA-I was dissolved in normal saline.  After the equilibration period, increasing 
doses of BK (0 – 625 ng/kg) were injected into the rat to be followed by a single 
Each rat (n = 8) anaesthetised with sodium pentobarbitone (50 mg/kg) by 
intraperitoneal injection and placed on a surgical board. 
The trachea, left carotid artery and right jugular vein exposed surgically. 
A heparinised polyethylene tube connected to a pressure transducer inserted into the 
left carotid artery for continuous BP measurement.  
The trachea cannulated to facilitate respiration. 
 
A polyethylene tube inserted into the right jugular vein for intravenous injection of 
test solutions.  
Small animal electrographic leads attached to the limbs of the rat to record the HR.  
The set up equilibrated for at least 30 min before injection of test solutions.  The rat 
kept warm (35 ± 2
 o
C) with a heating lamp throughout the experiment. 
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administration of FA-I (10 mg/kg) (with reference to Hoe, 2007) and then the same 
increasing doses of BK again.  A minimum interval of 3 min was allowed between each 
injection of BK whilst a minimum period of at least 10 min was given between the 
administrations of BK and FA-I to allow the BP to return to resting state.  Each injection 
was set at a fixed volume of 0.1 ml per 300 g rat body weight.  Changes in the BP due to 
the administration of BK and FA-I were obtained by calculating the difference between the 
BP before and the lowest BP after the injections.  The mean arterial pressure (MAP) was 
calculated using the formula: MAP = DBP + 1/3(SBP - DBP).  Figure 2.3 shows the 
photography of the set up for the measurement of BP and HR of rat. 
 
  
Cannulated  
jugular vein 
Cannulated carotid 
artery 
Cannulated 
trachea 
Electrocardiographic leads 
Heparinised saline 
Pressure 
transducer 
Anaesthetised 
 rat  
Data acquisition 
system 
BridgeAmp 
BioAmp 
Figure 2.3 : Setup of the experimental procedure for the measurement of blood pressure 
and heart rate in a rat. 
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2.5 In vitro assays 
2.5.1 In vitro effect of FA-I and its subfractions on angiotensin-converting enzyme 
activity  
 
The ACE inhibitory activity of G. procumbens was studied by using an in vitro 
ACE colourimetric assay of Hurst and Lovell-Smith, 1981 with some modifications.  The 
procedures for the in vitro ACE inhibitory activity assay are shown as follows:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.1 ml of HHL (20 mM) added into 0.4 ml of assay mixture (extracts + 20 mU ACE 
+ 0.8 M NaCl + 0.08 M H3BO3 buffer (pH 8.3).  
The mixture incubated in water bath at 37 
o
C for 15 min. 
0.5 ml of 1 M HCl added to stop the reaction. 
After 30 s, 0.5 ml of 1 M NaOH added to neutralise the reaction mixture. 
2.0 ml of diluent buffer (20 mM KH2PO4, pH 8.3) followed by 1.5 ml of colour 
reagent (3% cyanuric chloride in 1,4-dioxan) then added. 
The mixture vortex-mixed vigorously for 30 s and leaved for 5 min, then vortex-
mixed again.  
The mixture centrifuged at 3,000 rpm for 10 min.  
The absorbance of the supernatant measured by spectrophotometer at 382 nm 
against the reagent blank. 
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In order to prepare the enzyme blank, the terminating and neutralising solutions 
were added before the HHL; to prepare the reagent blank, the HHL solution was replaced 
with distilled water whereas for hippuric acid standards preparation, the HHL solution was 
replaced with standard HA solutions.   
For calculations, one unit of ACE activity is defined as the amount of enzyme 
required to produce one µmole of HA per minute at 37 
o
C.  The effect of FA-I and its 
subfractions on ACE activity was calculated by the following formula: 
 
 
Where:    A  = ACE activity in the absence of inhibitor 
    B  = ACE activity in the presence of inhibitor (plant extract) 
 
The IC50 value, which is the concentration of the fraction required to inhibit 50% of 
the ACE activity, was determined using linear regression analysis. 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
 
X 100% 
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2.5.2  In vitro effect of FA-I and its subfractions on neutral endopeptidase activity   
A two-steps assay widely used by Kiss et al., 2008, with some modifications was 
used in this study, as shown in the following: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 µl of SAAP-AMC (400 µM) added to 350 µl of HEPES-buffer with or without 
50 µl of extracts in eppendorf tubes.  
150 µl of NEP (5 mU) added to start the first reaction. 
 
The mixture incubated at 37 
o
C for 1 h. 
 
50 µl of phosphoramidon solution (50 µM) added to stop the reaction. 
20 µl of APN (1 : 235, v/v) added to start the second reaction. 
The mixture incubated at 56 
o
C for 1 h. 
 
800 µl acetone added to terminate the reaction. 
 
The fluorescence of the released NEP measured at  
λexcitation = 355 nm and λemission = 460 nm 
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The effect of FA-I and its subfractions on NEP activity was calculated by the 
following formula: 
INEP=  [(Itotal - IAPN)/(100 - IAPN)]x100 
Where:   Itotal  =  100 - (F1 / K0) x 100  
   IAPN  =  100 - (F2 / K0) x 100 
 
All the measurements are fluorescent and represented as P1, P2, K0 and K: 
                                      F1= P1 - K and F2 = P2 – K 
Where:   P1  =  Fluorescence of sample with extract 
   P2  =  Fluorescence of sample with extract added in second reaction  
    (effect of extract on APN activity)       
 
     K0  =  Fluorescence of sample without extract 
     K  =  Fluorescence of sample with extract without enzyme 
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2.6 Effect of orally administered FA-I on blood pressure of spontaneously 
hypertensive and Wistar-Kyoto rats 
In this study, SHR (n = 7) and WKY (n = 8) rats were used.  In at least 7 days prior 
to the experiment, the rats were trained to enter the restraint cage and their SBPs were 
measured.  On the experimental day, FA-I was dissolved in distilled water and 
administered orally to rats at doses of 50, 100 and 200 mg/kg.  Control rats were 
administered with same amount of distilled water.  The SBP was measured by tail-cuff 
method with a device connected to a PowerLab setup before and also 2, 4, 6, 8, 24 h after 
administration.  Figure 2.4 shows the setup for a rat kept in a restraint cage and its SBP was 
measured by a cuff connected to a PowerLab setup. 
 
 
 
 
 
 
  
Restraint cage 
Cuff 
PowerLab computer system 
Figure 2.4 : Measurement of rat systolic blood pressure of rat by tail-cuff method. 
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2.7 Effect of proteases on angiotensin-converting enzyme inhibitory activity of  
FA-I 
 
 The stability of FA-I to maintain the ACE inhibitory activity against proteases 
pepsin, trypsin and chymotrypsin was assessed individually by the method of Kuba et al, 
2003 with slight modifications.  In this in vitro assay, FA-I (0.25 – 2 mg/ml) was mixed 
with 0.2 ml of 0.05% (w/v) pepsin, chymotrypsin or trypsin solution.  Pepsin was dissolved 
in 0.1 M HCl at pH 2.0 whereas chymotrypsin and trypsin were both dissolved in 0.1 M 
potassium phosphate buffer at pH 8.0.  The mixture was incubated at 37 
o
C for 6 h, after 
which it was boiled for 10 min to stop the digestion.  Each sample was then centrifuged at 
3,000 rpm for 20 min and the supernatant was collected and freeze-dried before it was sent 
for the measurement of ACE inhibitory activity (refer section 2.5.1).  
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2.8 Data analyses 
When the cumulative concentration-response curves of Ang I or Ang II were 
examined, the contractions in the presence of FA-I were calculated as a percentage of the 
highest contractile response obtained in the absence of FA-I.  This contractile response 
evoked by the highest concentration of Ang I or Ang II was designated as Emax.  The pEC50 
value (-log EC50 ), determined from the EC50 value (the concentration required to produce a 
half-effect in the concentration-response curves) was calculated from individual log 
concentration-response curves of the Ang I or Ang II by sigmoidal non-linear regression 
analysis within the 95% confidence intervals using GraphPad Prism
®
 v.4.00 (GraphPad 
Software Inc., La Jolla, CA, USA).  The vasorelaxant response to BK was measured from 
the plateau of the PE-induced contraction and expressed as a percentage (%) relaxation of 
the PE-induced contraction.  The IC50 value, which is the concentration of extracts to 
inhibit 50% of ACE or NEP activity, was obtained from dose-response curves by linear 
regression. 
 
2.9 Statistical analyses 
All values are expressed as mean ± SEM for n number of rats or separate 
experiments.  Statistical differences for in vitro studies were evaluated by one-way analysis 
of variance (ANOVA) while student‘s t-test was used for in vivo studies.  A probability 
level of less than 0.05 (p<0.05) was considered to be significantly different.   
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CHAPTER 3 - RESULTS 
3.1  Extraction and fractionation of Gynura procumbens leaves 
 Gynura procumbens leaves were ground to powder form and extracted sequentially 
with several solvents to obtain FA-I.  The FA-I fraction on TLC plates sprayed with 
ninhydrin reagent was shown in Figure 3.1.  The yield of each solvent extract is shown in 
Figure 3.2.  Heating on FA-I at TLC plates sprayed with ninhydrin reagent revealed five 
different fractions (FA-Ia – FA-Ie) with retention factor (Rf) values of 0.21, 0.31, 0.45, 0.53 
and 0.66 respectively (Figure 3.2).     
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 : Chromatogram of a partially purified aqueous fraction (FA-I) on thin layer 
chromatography (TLC) plates after being sprayed with ninhydrin reagent.  The dark 
circle reveals FA-Ia.  
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Fractionated with  
water-saturated n-butanol 
 
Butanolic extract 
(10.0 g; 2.0%) 
FA-I 
(0.76 g; 76.0% of 1.0 g FA) 
 
Dried G. procumbens leaves 
(500 g) 
Crude ethanolic extract 
(60.0 g; 12.0%) 
Aqueous ethanolic extract 
 
Hexanic extract 
(18.0 g; 3.6%) 
  
 
 
Final aqueous extract (FA) 
(15.0 g; 3.0%) 
Figure 3.2 : Flow chart of extraction and fractionation of the leaves of Gynura 
procumbens (All % values in parenthesis indicate % yield of each fraction obtained 
from the original dried leaves weight except for FA-I which was calculated from 1 g of 
FA). 
FA-Ie (Rf : 0.66) 
FA-Id (Rf : 0.53) 
FA-Ic (Rf : 0.45) 
FA-Ib (Rf : 0.31) 
FA-Ia (Rf : 0.21) 
 
Ethanolic extract 
(13.4 g; 2.7%) 
Aqueous extract 
 
Extracted with 96% ethanol 
 
Sephadex LH-20 gel 
filtration chromatography 
 
Silica gel 60 F254 TLC plate  
B : A : W (4 : 1: 5, v/v, 
upper layer) 
 
Defatted with hexane 
 
Evaporated in vacuo 
 
63 
 
3.2 In vitro vascular tension studies 
3.2.1   Effects of FA-I pretreatment on angiotensin I-induced contraction 
Pretreatment with FA-I at 1.0 x 10
-4 
and 1.0 x 10
-3 
g/ml inhibited the Ang I-induced 
contraction of both endothelium-intact (Figure 3.3a) and -denuded (Figure 3.3b) aortic 
rings in a concentration-dependent manner with significant (p < 0.01) reduction in the Emax 
values.  Furthermore, rings that were kept intact (Figure 3.3a) relaxed significantly (p < 
0.05) more than those that were denuded of endothelium (Figure 3.3b). 
 
3.2.2 Effects of FA-I pretreatment on angiotensin II-induced contraction 
Experiments were then carried out with endothelium-intact and -denuded aortic 
rings to study the involvement of endothelium in the response of FA-I to the contraction 
evoked by Ang II.  Results show that pretreatment of endothelium-intact aortic rings with 
FA-I attenuated the contraction caused by Ang II (Figure 3.4a), with the Emax values being 
significantly (p < 0.001) decreased when compared with controls.  However, exposure of 
endothelium-denuded aortic rings to FA-I for 20 min before the addition of increasing 
concentrations of Ang II did not blunt the contractions induced by Ang II (Figure 3.4b).  
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Figure 3.3 : Effects of a partially purified aqueous fraction (FA-I) on angiotensin I-
induced contraction in (a) endothelium-intact (Endo +) and (b) endothelium-denuded 
(Endo -) aortic rings.  The effects were determined in the absence or presence of FA-I (1.0 
x 10
-4 
or 1.0 x 10
-3
 g/ml).  Values are mean ± S.E.M. (n = 6). **p < 0.01; ***p < 0.001 
compared with controls (without FA-I) and 
+
p < 0.05; 
+++
p < 0.001 compared with Endo +.   
 
Figure 3.4 : Effect of a partially purified aqueous fraction (FA-I) on angiotensin II-induced 
contraction in (a) endothelium-intact (Endo +) and (b) endothelium-denuded (Endo -) aortic 
rings.  The effect was determined in the absence (without FA-I) or presence of FA-I (1.0 x 
10
-4 
or 1.0 x 10
-3
 g/ml).  Values are mean ± S.E.M. (Endo +, n = 7; Endo –, n = 6) ***p < 
0.001; compared with controls (without FA-I).   
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3.2.3 Effects of FA-I pretreatment on Ang II-induced contraction of aortic rings in 
the presence of N
ω
-nitro-L-arginine methyl ester or indomethacin 
 
To further study the role of endothelial factors in the action of FA-I, Ang II-induced 
contraction in endothelium-intact rings were performed in the presence of both FA-I and  
L-NAME or indomethacin.  Results show that pretreatment of FA-I at 1.0 x 10
-4 
and        
1.0 x 10
-3
 g/ml in the presence of L-NAME (Figure 3.5a) or indomethacin (Figure 3.5b) did 
not cause any significant changes in the Emax values for Ang II as compared to controls.  
In aortic rings pretreated with L-NAME, although there were no significant changes 
in Emax values, the concentration-response curves of Ang II are shifted to the right (Figure 
3.5a) with a significant (p < 0.05) decrease in pEC50 values (Table 3.1).  Similarly, 
preincubation of FA-I and indomethacin also shifted the concentration-response curve to 
the right (Figure 3.5b), with a significant (p < 0.01) reduction of pEC50 values for Ang II in 
the presence of FA-I at 1.0 x 10
-3
 g/ml (Table 3.1).  These results show that the eNOS and 
COX pathways may be involved in the response of FA-I on Ang II-induced contraction of 
aortic rings.  
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FA-I 
(x 10
-3
 g/ml) 
pEC50 
L-NAME Indomethacin 
0 7.84 ± 0.06 7.89 ± 0.08 
0.1   7.61 ± 0.12* 7.75 ± 0.16 
1.0     7.54 ± 0.11**     7.53 ± 0.14** 
 
 
 
 
 
 
 
 
Table 3.1 : Effect of a partially purified aqueous fraction (FA-I) on the pEC50 values for 
Ang II-induced contraction of aortic rings pretreatment with L-NAME or indomethacin. 
Values are mean ± S.E.M. (n = 6) 
*p < 0.05; **p < 0.01 compared with controls (without FA-I). 
Figure 3.5 : Effect of a partially purified aqueous fraction (FA-I) on angiotensin II-induced 
contraction in endothelium-intact aortic rings preincubated with (a) N
ω
-nitro-L-arginine 
methyl ester (L-NAME) or (b) indomethacin.  The effect was determined in the absence or 
presence of FA-I (1.0 x 10
-4 
or 1.0 x 10
-3
 g/ml).  Values are mean ± S.E.M. (n = 6).   
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3.2.4 Effects of FA-I pretreatment on bradykinin-induced relaxation of 
phenylephrine-precontracted aortic rings 
 
Bradykinin (1 x 10
-11
 – 1 x 10-6 M) dose-dependently relaxed PE-induced 
contraction of aortic rings.  This observation was significantly (p < 0.05) enhanced by 
pretreatment of aortic rings with FA-I (Figure 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 : Effect of a partially purified aqueous fraction (FA-I) on bradykinin-induced 
relaxation of aortic rings precontracted with phenylephrine.  The effect was determined in 
the absence (without FA-I) or presence of FA-I (1.0 x 10
-4 
or 1.0 x 10
-3
 g/ml).  Values are 
mean ± S.E.M. (n = 8).  *p < 0.05 **p < 0.01 compared with controls (without FA-I).  
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3.3   Effects of FA-I on the action of bradykinin on mean arterial pressure and 
heart rate of rats  
 
Intravenous administrations of BK at different doses induced immediate and 
significant (p < 0.05) decrease in the MAP (Figure 3.7a) and HR (Figure 3.7b) of rats.  
After pretreatment with 10 mg/kg FA-I, the BP lowering effect produced by BK was 
markedly (p < 0.05) greater.  The difference in the hypotensive effect of BK before and 
after FA-I pretreatment became significant (p < 0.05) at doses of 78, 156, 312 and 625 
ng/kg.  Bradykinin also decreased the HR but there was no significant difference in the 
bradycardic effect between before and after FA-I administration.  Pre-dose baseline levels 
were recovered within 10 min after BK administration.      
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Figure 3.7 : Effect of intravenous bradykinin on the (a) mean arterial pressure (MAP) and 
(b) heart rate (HR) of anaesthetised rats before and after 10mg/kg FA-I administration. 
Values are mean ± S.E.M. (n = 8).  *p < 0.05; **p < 0.01; ***p < 0.001 compared with  
0 ng/kg bradykinin and 
+
p < 0.05; 
++
p < 0.01 compared with controls (before FA-I).   
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3.4 In vitro assays 
3.4.1 In vitro effect of FA-I and its subfractions on angiotensin-converting enzyme 
activity 
 
Figure 3.8 displays the effect of FA-I on ACE activity.  Fraction FA-I was shown to 
inhibit ACE activity in a concentration dependent manner with an IC50 value of 0.52 mg/ml.   
 
 
 
 
 
 
 
 
 
Among the subfractions of FA-I, FA-Ia, FA-Ib and FA-Ic were found to have 
inhibitory effects on ACE activity by more than 50% at a concentration of 1.0 mg/ml each 
(Figure 3.9).  The IC50 values for FA-Ia, FA-Ib and FA-Ic were 0.43, 0.95 and 0.58 mg/ml 
respectively (Table 3.2).  Subfractions FA-Id and FA-Ie did not cause any obvious 
inhibition of ACE activity (Figure 3.9). 
   
 
  
 
 
FA-I subfractions IC50 (mg/ml) 
FA-Ia 0.43 
FA-Ib 0.95 
FA-Ic 0.58 
FA-Id - 
FA-Ie - 
Table 3.2 : IC50 values of FA-I subfractions. 
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Figure 3.8 : Effect of a partially purified aqueous fraction (FA-I) on angiotensin-
converting enzyme (ACE) activity.  Data are means (duplicate assays).  
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Figure 3.9 : Angiotensin-converting enzyme (ACE) inhibition by (a) FA-Ia, (b) FA-Ib, (c) 
FA-Ic, (d) FA-Id and (e) FA-Ie.  Data are means (duplicate assays).   
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3.4.2 In vitro effect of FA-I and its subfractions on neutral endopeptidase activity   
Figure 3.10 displays the effect of FA-I on NEP activity.  Fraction FA-I was shown 
to inhibit NEP activity in a concentration dependent manner with an IC50 value of           
225 µg/ml.  Among the subfractions of FA-I, none of them shows obvious NEP inhibitory 
activity (Figure 3.11).   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 : Effect of a partially purified aqueous fraction (FA-I) on neutral endopeptidae 
(NEP) activity.  Data are means (triplicate assays).   
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Figure 3.11 : Neutral endopeptidase (NEP) inhibition by (a) FA-Ia, (b) FA-Ib, (c) FA-Ic, 
(d) FA-Id and (e) FA-Ie.  Data are means (triplicate assays).   
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3.5 Effect of orally administered FA-I on blood pressure of spontaneously 
hypertensive and Wistar-Kyoto rats 
Figure 3.12 shows the time-course changes in the SBP of SHR and control WKY 
rats after a single oral administration of FA-I (50, 100 or 200 mg/kg) or vehicle (distilled 
water).  An oral dose of FA-I was able to cause a significant (p < 0.05) dose-dependent 
decrease in the SBP especially at the higher doses when compared to controls (Figure 3.12). 
In the SHR rats, there is a tendency for the SBP to return to the initial level within 24 h 
after oral administration and the highest antihypertensive effect of FA-I occurred at 6 h 
after the oral administration (Figure 3.13).   
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Figure 3.12 : Change in systolic blood pressure after a single orally administered of 
partially purified aqueous fraction (FA-I) in (a) Wistar-Kyoto (WKY) and (b) 
spontaneously hypertensive (SHR) rats.  Values are mean ± S.E.M. (WKY, n = 6; SHR, n 
= 7).  *p < 0.05, **p < 0.01 and ***p < 0.001 compared with vehicles (distilled water).    
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3.6 Characterisation of FA-I subfractions  
Among the five subfractions of FA-I, only FA-Ia, FA-Ib and FA-Ic showed 
bioactive activity (Figure 3.9, Figure 3.11).  However, when subjected to 
1
H NMR 
spectrometer, no conclusive data could be observed for FA-Ia (Appendix E), FA-Ib 
(Appendix F) and FA-Ic (Appendix G).  Nevertheless, when using other spectrometric 
analyses, a putative 16 carbon compound was obtained in FA-Ia.  
The structure of FA-Ia, elucidated by 
1
H (Appendix E) and 
13
C NMR (Appendix H) 
spectroscopies, shows the presence of aliphatic protons within chemical shifts  12 ppm, 
protons adjacent to an olefin and/or a carbonyl group within  34 ppm and olefinic 
protons within  56 ppm (by 1H NMR) with a total of 16 carbons (by 13C NMR).  Four 
CH/CH3, ten CH2 and two quaternary carbons were revealed in the DEPT spectrum 
Figure 3.13 : Change in systolic blood pressure in Wistar-Kyoto (WKY) and 
spontaneously hypertensive (SHR) rats at 6 hours after a single orally administered of   
partially purified aqueous fraction (FA-I).  Values are mean ± S.E.M. (WKY, n = 6; SHR, 
n = 7).  *p < 0.05, **p < 0.01 and ***p < 0.001 compared with vehicles (distilled water).    
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(Appendix I).  The mass spectrum data obtained from LC-MS showed a molecular ion at 
m/z 279 [M + H]
+
 (Appendix J) suspected for C16H22O4.  Strong infrared absorptions for 
functional groups hydroxyl (OH), 3297 cm
-1
; aliphatic (C-H), 2923 and 2854 cm
-1
; 
carbonyl (C=O), 1740 cm
-1
 and ether (C-O), 1047 cm
-1
 stretching frequencies were found 
in the molecule (Appendix K).  However, the definitive structure of FA-Ia remains 
unresolved. 
 
3.7 Effect of proteases on angiotensin-converting enzyme inhibitory activity of  
FA-I 
 
Figure 3.14 shows the ACE inhibitory activity of FA-I without and after the 
treatment of proteases.  Overally, the ACE inhibitory activity of FA-I was still preserved 
after the treatment of proteases.  There was a slight decrease in ACE inhibitory activity of 
FA-I, as indicated by increase in their IC50 values, after pepsin, trypsin or chymotrypsin 
treatment (Table 3.3). 
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Digestion IC50 of FA-I (mg/ml) 
None 0.52 
Pepsin 0.70 
Trypsin 0.60 
Chymotrypsin 0.64 
(a) Without treatment 
(c) Chymotrypsin treatment 
(b) Pepsin treatment 
treatment 
Figure 3.14 : The angiotensin-converting enzyme (ACE) inhibitory activity of FA-I (a) 
without and after (b) pepsin, (c) chymotrypsin and (d) trypsin.  Data are means (duplicate 
assays).   
Table 3.3 : The effect of digestive enzymes on the IC50 values of FA-I. 
(d) Trypsin treatment 
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CHAPTER 4 - DISCUSSION 
4.1 In vitro vascular tension studies  
In vitro vascular tension study was performed to extend previous studies that clearly 
demonstrated the BP-lowering effects of G. procumbens by inhibition of ACE activity 
(Hoe et al, 2007).  Aortic rings were used to study the effect of FA-I on the contraction 
caused by Ang I and Ang II because ACE is abundantly present in the aortic rings
 
(Andre et 
al, 1990; Egleme et al, 1990).  As shown in Figure 3.3, preincubation with FA-I 
significantly inhibited the Ang I-induced vasocontraction in both endothelium-intact and    
-denuded aortic rings, with the degree of relaxation produced in endothelium-intact rings 
being significantly (p < 0.05) greater than that obtained in the denuded ones.  These 
observations indicate that the actions of FA-I are more enhanced in the presence of the 
endothelium, probably because of the presence of NO (Sandoo et al, 2010) and PGI2 
(DalBo et al, 2008).  The effects are likely to be mediated through the newly converted 
Ang II from Ang I by ACE that are abundantly found in aortic rings (Andre et al, 1990; 
Egleme et al, 1990) as Ang I per se appears to have no physiological function
 
(Peach, 1977; 
Hayashi and Kimoto, 2010).  This finding also further confirms the previous studies (Hoe 
et al, 2007) that FA-I inhibits ACE which then reduces the production of Ang II and causes 
a drop in the contractile response of Ang II.  
Angiotensin II is a potent vasoconstrictor and acts mainly through the widely 
distributed AT1R to increase BP (Lote, 2006).  Increased RAS activity which leads to the 
increase in Ang II has been implicated as a major contributing factor in the development of 
hypertension (Navar et al, 2011).  The present study shows that FA-I is able to inhibit the 
Ang II-induced contraction of aortic rings with endothelium (Figure 3.4a).  Experiments 
were then carried out on endothelium-denuded aortic rings to investigate the involvement 
of endothelium on the effect of FA-I on Ang II-induced contraction of aortic rings.  In 
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endothelium-denuded aortic rings, FA-I did not appear to have a significant effect on the 
contraction evoked by Ang II (Figure 3.4b).  This may exclude the notion that FA-I could 
be an AT1R blocker as AT1R blockers are known to inhibit Ang II-induced contractions in 
endothelium-denuded aortic rings as well (d'Uscio et al, 1998; Watts et al, 1998).  Hence, 
this strongly suggests that the inhibitory effect of FA-I on the vascular contraction is 
entirely endothelium dependent.  
It is well known that the endothelium plays an important role in the regulation of 
vascular tone by releasing both relaxant and contractile factors in response to chemical and 
physical stimulation (Villar et al, 2006; DalBo et al, 2008; Sandoo et al, 2010).  The 
vasorelaxant substances released by endothelial cells include NO mainly produced by 
eNOS (Sandoo et al, 2010) and PGI2 produced by the COX pathway
 
(DalBo et al, 2008).  
In the present study, pEC50 value was used to study the influence of L-NAME and 
indomethacin because there is no significant difference in the Emax values among the aortic 
rings preincubated with L-NAME (Figure 3.5a) or indomethacin (Figure 3.5b).  The 
inhibitory effect of FA-I on the Ang II-induced contraction of aortic rings was reduced in 
the presence of L-NAME (Figure 3.5a) or indomethacin (Figure 3.5b), with significant           
(p < 0.01) reduction in pEC50 values (Table 3.1).  A reduced pEC50 value shows that the 
graph is shifted to the right, indicating that in the presence of FA-I, the contractile effect of 
Ang II is reduced and more Ang II is needed to cause the same level of contraction.  These 
findings support the notion that FA-I is able to counteract the contractile response of Ang II 
by stimulating the release of vasorelaxing factors via both the eNOS and COX pathways.  
In the presence of L-NAME in which eNOS is inhibited, FA-I is able to decrease Ang II-
induced contraction probably by triggering the release of PGI2.  Similarly, in the presence 
of indomethacin, FA-I may be able to stimulate the release of NO, despite COX being 
inhibited.   
80 
 
4.2 Effects of FA-I on bradykinin by in vitro and in vivo studies 
Bradykinin is a vasodilator produced in the kallikrein-kinin system
 
(Campbell, 2000) 
in which most of the effects of BK are being mediated by B2 receptor under normal 
conditions
 
(Nishiyama and Kim-Mitsuyama, 2010).  Inhibition of ACE may partly 
potentiate the actions of BK, by either an indirect action on B2 receptor (Deddish et al, 
2002) or direct activation of B1 receptor
 
(Erdos, 1999) to confer additional benefits to the 
CVS.  In order to study the effects of FA-I on hypotensive and vasodilatory effects of BK, 
both in vitro and in vivo methods with reference to the methods performed by Anozie et al, 
2007 and Maia et al, 2004, with slight modifications.   
In the in vitro study, BK evoked a dose-dependent relaxation of PE-induced 
contraction of aortic rings, similar to the study of that reported by Anozie et al, 2007.  As in 
the in vivo study, BK produced a dose-dependent hypotensive effect, similar to the report 
by Maia et al, 2004.  At the highest dose of BK (625 ng/kg), the drop in MAP is smaller, 
but not significant when compared to the previous dose (312 ng/kg).  This may be due to 
the baroreceptor reflex (Guyton and Hall
3
, 2006) in the rats to prevent further drop in MAP.  
In this in vivo study, the MAP, which is the pressure that drives the blood into tissues 
during the cardiac cycle, was used as the parameter for BP comparison because it minimise 
the inaccuracies of SBP and DBP (Smulyan and Safar, 2011).  The formula of MAP that 
used in this study was MAP = DBP + 1/3(SBP - DBP) because it is the most common 
formula that is being used worldwide (Smulyan and Safar, 2011).        
Studies shown here demonstrated that in the presence of FA-I, the vasorelaxant (in 
vitro study) and BP-lowering (in vivo study) effects of BK are greater.  In the study on 
aortic rings in the presence of FA-I, the relaxation effect brought about by BK on PE-
precontracted endothelium-intact aortic rings is increased (Figure 3.6).  However, parallel 
experiments on endothelium-denuded rings were not performed as it is well-established 
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that vasodilation caused by BK is entirely endothelium dependent (Vanhoutte, 2001).  In 
the in vivo studies, the BP-lowering effect of BK was also greater after administration of 
FA-I (Figure 3.7a).  Although BK is known to cause bradycardia (Wang et al, 2003), the 
infusion of FA-I did not alter the bradycardic effect of BK (Figure 3.7b).  This could be due 
to the baroreceptor reflex (Wang et al, 2003) being involved in preventing further reduction 
in the HR brought about by FA-I.  Hence, FA-I is able to potentiate the hypotensive effect 
of BK probably by enhancing the vasodilator activities of BK through inhibition of ACE or 
NEP, but without alteration in HR.    
Other than that, it is speculated that FA-I may potentiate the hypotensive effect by 
BK through the vasodilatory effect of Ang (1-7) which is increased after inhibition of ACE 
(Fernandes et al, 2001).  The FA-I may also possess antioxidant effect that preserves the 
production of NO which is reduced due to oxidative stress produced by PE (Hao et al, 
2006).  Nevertheless, the exact mechanism responsible for the BK potentiation effects of 
FA-I remains to be elucidated. 
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4.3 Vasopeptidase inhibitory activities of FA-I and FA-I subfractions 
One of the most popular VPIs, omapatrilat, had high incidence of life-threatening 
side-effect angioedema and was thus withdrawn by FDA (Song and White, 2001).  
Searching for potential VPIs from natural products may alleviate the side-effects, especially 
that of angioedema.  Although VPI is deemed to be more superior to ACEI or NEPI alone, 
studies on potential dual ACE/NEP inhibitory activities from natural products have less 
popular attention.  Examples of plants with dual ACE/NEP inhibitory activities are 
Ligustrum vulgare (Kiss et al, 2008) and Epilobium angustifolium (Kiss et al, 2006).  Since 
FA-I was shown to have strong ACE inhibitory activity (Hoe et al, 2007), it would be 
interesting to investigate whether this plant has NEP inhibitory activity as well. 
In studying the potential dual ACE/NEP inhibitory activities, spectrophotometric 
method (for measurement of ACE activity) and spectrofluorometric method (for 
measurement of NEP activity) were used.  Both of these methods are volume sensitive and 
the enzymes are sensitive to the environment and need to be handled with care.  The 
amount of FA-I and its subfractions used were referred to the previous study with little 
adjustment (Hoe et al, 2007).  Micrograms of extracts were used in NEP activity study as 
reference to Kiss et al, 2008 (Kiss et al, 2008). 
Result shows that FA-I has strong ACE inhibitory activities (Figure 3.8), which is 
similar to that reported by Hoe et al, 2007.  Among the FA-I subfractions, FA-Ia, FA-Ib 
and FA-Ic inhibited ACE activities at 1.0 mg/ml (Figure 3.9).  In this study, an ACEI drug, 
captopril (2.6 mg/ml) is able to inhibit 98.44% of ACE activity.  The ACE inhibitory effect 
of FA-I and its bioactive subfractions seem to be comparable to captopril but no further 
conclusion can be made because only a single dose of captopril was used.  Among the FA-I 
subfractions, FA-Ia may have the strongest ACE inhibitory activity because it has the 
lowest IC50 value (Table 3.2).  These findings show that some FA-I subfractions retain the 
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ACE inhibitory activity and the ACE inhibitory compounds that are present in FA-I may 
also present in these subfractions.  
Besides the ACE inhibitory activity, our study successfully shows that FA-I 
possesses some NEP inhibitory activity, with IC50 value of 225 µg/ml (Figure 3.10).  The 
NEP inhibitory effect is far weaker when comparing to a single dose of phosphoramidon 
(100 µg/ml), a reference drug used in this study, which decreases 97.9% of NEP activity.  
This may be because FA-I is only a partially purified fraction but the phosphoramidon is a 
popular NEP inhibitor drug.  However, this NEP inhibitory activity diminishes in FA-I 
subfractions (Figure 3.11).  It is speculated that there may exist more than one NEP 
inhibitory compounds present in FA-I.  In order to exhibit strong NEP inhibitory effect, 
these compounds need to act synergistically and the amount of NEP inhibitory compounds 
that are present in each FA-I subfraction may not be enough to react to give strong 
inhibitory effects (Colegate and Molyneux, 2008).  Another postulation is the loss of 
bioactive compounds during separation step (Colegate and Molyneux, 2008).  The presence 
of NEP inhibitory activity in FA-I but not in its subfractions could also be due to the 
existence of unknown compounds in FA-I that are not revealed at the TLC plate by 
ninhydrin reagent.  It is also possible that FA-I subfractions may also act at the allosteric 
sites of the enzyme that give a conformational change in the enzyme to enable the binding 
of other subfractions.         
 The dual ACE/NEP inhibitory effect of FA-I may also be responsible for the 
potentiation of the hypotensive effect of BK.  This is because the main enzymes 
responsible for the hydrolysis of BK are ACE and NEP and the inhibition of these enzymes 
would result in an increase in the level of BK to enhance vasodilation to cause a drop in BP 
(Sharma and Al-Sherif, 2011).   
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4.4 Effect of orally administered FA-I on blood pressure of rats  
At present, there are many methods being used to measure the BP of rats.  Among 
these methods, radiotelemetry is claimed to be the most efficient and accurate method in 
measuring the BP of rats (Mills et al, 2000; Van Vliet et al, 2000).  Tail-cuff method was 
adopted in this study because this method has the main advantage of no surgical and 
anesthesia procedures which minimise the risk of infecton. 
In order to minimise false positive readings brought by changes in BP due to 
heating and restraining (Irvine et al, 1997), rats were subjected to same sized restrainers, 
same preheating time and heating temperature; and similar environment.  Training of rats 
prior to the experimental procedures made the rats better at adapting to the restraining 
conditions and they remained calmer in the restrainers. 
Some studies have shown that antihypertensive agents may lose their effects after 
being treated orally (Li et al, 2004).  Thus, oral feeding of FA-I on SHR and WKY rats 
were performed in this study.  The SHR rat was chosen because it is the most widely used 
hypertensive animal model and the incidence of developing hypertension is 100% (Yamori 
and Okamoto, 1973) whereas the normotensive WKY rats serve as controls for SHR rats 
(Kurtz and Morris, 1987).   
A single oral administration of FA-I exerted antihypertensive effect on SBP in SHR 
rats, with the highest effect occurring at 6 h after the administration (Figure 3.12b).  
However, no significant suppression in SBP was found in normotensive WKY rats except 
for the highest concentration, 200mg/kg of FA-I (Figure 3.12a).  This shows that FA-I has 
antihypertensive effect and a lower dose of FA-I may be safe to normotensive subjects.  In 
order to cause antihypertensive effect after oral administration, the agents need to reach the 
blood circulation (Vermeirssen et al, 2004).  Therefore, active substances in FA-I are 
believed to be able to reach the blood circulation in an active form after oral treatment.   
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4.5 Effect of proteases on angiotensin-converting enzyme inhibitory activity of  
FA-I and nuclear magnetic resonance studies on FA-Ia   
 
The results show that FA-I is able to retain most of its ACE inhibitory activity after 
pepsin, trypsin and chymotrypsin treatment with little increase in IC50 values (Table 3.3).  
This protease study indicates that the active compounds in FA-I may not be amino acid and 
they can withstand the effects by proteases.   
Ninhydrin (2,2-dihydroxyindane-1,3-dione) is a chemical used to detect ammonia, 
primary and secondary amines.  When reacting with these amines, a deep blue or purple 
colour stain is produced on the TLC.  Hence, ninhydrin is commonly used to detect amines 
in peptides or amino acids (Carey et al, 2010).  However, this ninhydrin staining test can 
only be used as a prepliminary phytochemical screening method because not all the amine-
containing compounds give positive results with ninhydrin and false positive 
results were also reported in non-amine-containing compounds (Carey et al, 2010).  A 
more reliable structural characterisation method is NMR spectroscopy (Colegate and 
Molyneux, 2008).  An amine-containing compound, i.e. amino acid could be detected 
explicitly by using 
1
H-NMR and 
13
C-NMR.  The 
13
C-NMR chemical shifts for an amino 
acid for example are in the range of 53.1 – 63.3 ppm (C-NH2) and 174.1 – 177.6 ppm 
(COOH) (Appendix L) (Wishart and Nip, 1998).  In the case of fraction FA-Ia, no amine or 
amino acid functional group was detected in the 
1
H-NMR and 
13
C-NMR.  Hence, FA-Ia is 
not an amino acid.  This is contrary to the study by Hoe et al, 2007 who postulated that FA-
I may be peptides. 
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4.6 General discussion and future studies 
 Hypertension is the most important risk factor for cardiovascular mortality and 
morbidity worldwide.  Although many types of antihypertensive treatments are available 
either clinically or traditionally, the prevalence of hypertension remains high and keeps on 
increasing (Kim et al, 2010).  Many studies have been carried out in search of novel 
antihypertensive treatments.   
Natural products with great structural diversities have made them valuable sources for 
the discovery of novel antihypertensive drugs.  The present study has shown some advance 
findings of the plant G. procumbens.  It is found to be being able to inhibit significantly           
(p < 0.05) the contraction brought by Ang II, probably via activation of the release of NO and 
PGI2 or it may act on an unknown receptor which is responsible for the contraction of Ang II.  
Future studies may be carried out to identify this receptor which may be present in the 
vasculars. 
Bradykinin has been known to contribute to the cardioprotective effects of ACEIs 
(Murphey et al, 2003).  Previous findings have shown that G. procumbens has strong ACE 
inhibitory activities (Hoe et al, 2007) and study was carried out to test whether this plant has 
effects on BK.  Results presented here have shown that the BP-lowering effect of BK is 
enhanced which may be caused by the greater vasodilatory effect of BK in the presence of plant 
extract.  One of the possible pathways other than the ACE and NEP inhibition, is activation of 
B1 or B2 receptors which can be explored in future. 
Acute oral feeding studies showed that the antihypertensive effect of G. procumbens is 
still preserved after going through the gastrointestinal system.  This is a great finding which 
gives clue that it may be effective when applied orally to the human.  The possible adverse 
side-effects that may be arising have not studied and this remains to be explored.  
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Finally, in order to contribute to the antihypertensive treatments, the compounds are 
needed to be isolated, identified and produced industrially.  It is necessary to identify the 
bioactive compounds that are responsible for the effects of G. procumbens, although one needs 
to take into account the heterogeneity of hypertension in order to evaluate the potential impact 
of treatment for the management of this disorder.  The systems in the human body react 
differently to the hypertension and hypertensive patient react differently to the antihypertensive 
treatments.  Side-effects of the drugs that are arising should not be ignored.  Natural products 
represent the major source of chemical diversity for antihypertensive screening purposes and 
communication among the experts such as botanists, chemists, clinicians and natural products 
researchers should be well established so that the biodiversity that exists in nature is not lost for 
antihypertensive drug discovery.  
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CHAPTER 5 - CONCLUSIONS 
 This study conclusively demonstrates and extends previous investigations that FA-I, 
fractionated from the leaves of G. procumbens, has potent BP-lowering effect acting via 
dual ACE/NEP inhibitory activity as well as BK enhancement.  Finding of FA-I being able 
to antagonise the vasoconstrictive effect of Ang II is reported.  The effect of FA-I on Ang 
II-induced contraction of aortic rings appears to be mediated by an endothelium-dependent 
pathway that involves the activation of NO and COX mechanisms.  In addition, FA-I is 
able to enhance the BK effect, most probably by stimulation of the release of NO and PGI2.  
These findings are summarised in Figure 5.1.   
As part of our search for potential VPI from plant, this report indicates that FA-I has 
dual ACE/NEP inhibitory activity.  As far as can be ascertained, this is the first study that 
demonstrates the dual effect of G. procumbens.  Although only FA-I and not its 
subfractions show NEP inhibitory activity, ACE inhibitory activities are shown by FA-Ia, 
Fa-Ib and FA-Ic (Figure 5.1).   
This study also shows that FA-I has antihypertensive effect on SHR and little effect 
on WKY rats after it is being treated orally.  It is also able to withstand proteases to 
maintain most of its ACE inhibitory activity.  The NMR and HPLC-MS studies indicate 
that FA-Ia is a 16 carbon molecule suspected for C16H22O4 that has OH, aliphatic C-H, C=O 
and C-O functional groups.   
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Figure 5.1 : Extraction and fractionation of Gynura procumbens, the effects and 
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APPENDIX A - SEPHADEX LH-20 GEL FILTRATION CHROMATOGRAPHY 
 About 80 g of dry Sephadex LH-20 gel were swelled in distilled water and then 
packed into a glass column with stopcock (2.5 cm, i.d. x 75 cm, height).  Five grams of 
lyophilised FA dissolved in 5.0 ml of distilled water were applied to the column.  The 
column was eluted with distilled water continuously at a flow rate of 0.5 ml/min by using a 
peristaltic pump.  Caution was needed to avoid drying of the column.  A fraction collector 
was used and each tube collected about 6.0 ml of fractions.  The obtained fractions were 
then analysed by plotting on TLC aluminium plates coated with silica gel 60 F254 (20 cm x 
10 cm x 0.25 mm) with mobile phase being a combination of n-butanol : acetic acid : 
distilled water (B : A : W) (4 : 1 : 5 v/v, upper layer).  The TLC plates were developed 
twice and viewed under UV light at 365 and 254 nm.  The fractions that showed the same 
profile with the first fraction eluted were further confirmed by spraying with ninhydrin 
reagent before combining them together to obtain the FA-I fraction.  The FA-I was then 
lyophilised and stored at -20
o
C for future use. 
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APPENDIX B - PREPARATIVE THIN LAYER CHROMATOGRAPHY 
According to the study by Hoe et al, 2007, FA-I showed significant 
antihypertensive activity and yielded the highest amount, thus it was subjected to 
preparative TLC for further purification.  Thin layer chromatography aluminium plates 
coated with silica gel 60 F254 were used.  The FA-I solution was applied to several spots 
arranged in a straight line with each spot separated 1 cm.  The mobile phase was B : A : W 
(4 : 1 : 5, v/v, upper layer) and the TLC plates were developed twice.  After development, 
strips of 1.0 cm width were cut from the center and edges of the TLC plates.  The strips that 
cut out were sprayed with ninhydrin reagent and then compared with the unsprayed TLC 
plates to locate the positions of the FA-I subfractions.  Each region that was corresponding 
to each compound on the plate was scrapped off and collected in separate vials.  The 
compounds that were absorbed to the silica gel were desorbed by mixing them with 
methanol.  The vials were then centrifugated at 3,000 x g for 20 min.  This desorption 
process was repeated three times for maximum recovery of the compounds.  The methanol 
solvent was then evaporated to obtain the compounds from each region in TLC plates.   
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APPENDIX C - NINHYDRIN REAGENT 
Ninhydrin reagent is commonly used to detect amino acids, amines and peptides.  It 
reacts with amino acids and peptides to give a purple/red colour.  In this study, it was 
prepared by dissolving 0.2 g of ninhydrin in 100 ml of acetone.  After spraying the TLC 
plates with ninhydrin reagent, the plates were heated with hair dryer until colouration was 
seen.  Care must be taken not to leave any fingerprint on TLC plates as ninhydrin is 
sensitive to fingerprint.  
 
 
APPENDIX D - COMPOSITIONS OF KREBS-HENSELEIT SOLUTION 
Materials Composition (mM) 
NaCl 118.0 
KCl 4.70 
CaCl2 2.5 
MgSO4 1.2 
KH2PO4 1.2 
NaHCO3 24.9 
Glucose 11.1 
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APPENDIX E - 
1
H NUCLEAR MAGNETIC RESONANCE SPECTRUM (NMR) OF 
FA-IA AND THE TABULATED CHEMICAL SHIFTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Hydrogen* 
Chemical shift 
δ (ppm) 
H1 5.38 
H2 5.37 
H3 3.73 
H4 3.71 
H5 3.6 
H6 3.33 
H7 3.31 
H8 3.3 
H9 3.29 
H10 3.29 
H11 3.28 
H12 1.87 
H13 1.26 
H14 1.23 
  
*Unassigned 
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APPENDIX F - 
1
H NUCLEAR MAGNETIC RESONANCE SPECTRUM (NMR) OF 
FA-IB 
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APPENDIX G - 
1
H NUCLEAR MAGNETIC RESONANCE SPECTRUM (NMR) OF 
FA-IC 
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APPENDIX H - 
13
C NUCLEAR MAGNETIC RESONANCE SPECTRUM (NMR) 
OF FA-IA AND THE TABULATED CHEMICAL SHIFTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbon* 
Chemical shift  
δ (ppm) 
C1 104.45 
C2 92.81 
C3 82.9 
C4 78.48 
C5 74.83 
C6 73.73 
C7 73.53 
C8 73.42 
C9 72.55 
C10 72.33 
C11 70.47 
C12 63.14 
C13 62.54 
C14 61.32 
C15 29.89 
C16 23.35 
  *Unassigned 
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APPENDIX I - 2D DISTORTIONLESS ENHANCEMENT BY POLARISATION 
TRANSFER (DEPT) SPECTRUM OF FA-IA 
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APPENDIX J - LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (LC-MS) 
SPECTRUM OF FA-IA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX K - INFRARED SPECTRUM OF FA-IA 
 
 
 
 
 
 
 
  
  
MS Spectrum 
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APPENDIX L - SUGGESTED RANDOM COIL CHEMICAL SHIFTS (IN PPM) 
FOR THE COMMON AMINO ACIDS 
 
      
13
C     
Amino acid 
1
HN 
1Hα α 13Cβ 13CO 
Cys (red) 8.32 4.55 58.2 28.0 174.6 
Cys (oxd) 8.43 4.71 55.4 41.1 174.6 
Asp 8.34 4.64 54.2 41.1 176.3 
Glu 8.42 4.35 56.6 29.9 176.6 
Phe 8.30 4.62 57.7 39.6 175.8 
Gly 8.33 3.96 45.1 - 174.9 
His 8.42 4.73 55.0 29.0 174.1 
Ile 8.00 4.17 61.1 38.8 176.4 
Lys 8.29 4.32 56.2 33.1 176.6 
Leu 8.16 4.34 55.1 42.4 177.6 
Met 8.28 4.48 55.4 32.9 176.3 
Asn 8.40 4.74 53.1 38.9 175.2 
Pro − 4.42 63.3 32.1 177.3 
Gln 8.32 4.34 55.7 29.4 176.0 
Arg 8.23 4.34 56.0 30.9 176.3 
Ser 8.31 4.47 58.3 63.8 174.6 
Thr 8.15 4.35 61.8 69.8 174.7 
Val 8.03 4.12 62.2 32.9 176.3 
Trp 8.25 4.66 57.5 29.6 176.1 
 
(Wishart and Nip, 1998, with slight modifications) 
